var title_f25_41_26256="Press up PI";
var content_f25_41_26256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Press up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie face down on a towel or blanket on the floor. Extend hands in front of the body with elbows slightly bent. Press hands against floor and lift upper body. Keep hips in contact with the floor; keep low back and buttocks relaxed. Hold for 3 to 5 seconds. Rest and repeat 10 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26256=[""].join("\n");
var outline_f25_41_26256=null;
var title_f25_41_26257="Patient information: Neurofibromatosis type 1 (The Basics)";
var content_f25_41_26257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87115\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?26/23/27004\">",
"         How doctors monitor NF1",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Neurofibromatosis type 1 (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18518100\">",
"      <span class=\"h1\">",
"       What is neurofibromatosis type 1?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Neurofibromatosis type 1, also called NF1, is a genetic disorder that causes brown blotches and abnormal growths on the skin and along nerves. It is usually passed on in families, but children can sometimes get it even if their parents do not have it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518115\">",
"      <span class=\"h1\">",
"       What are the signs and symptoms of NF1?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The signs and symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Abnormal growths or tumors (called &ldquo;neurofibromas&rdquo;) that form on the skin and along nerves",
"       </li>",
"       <li>",
"        Blotches of light brown skin that look like giant freckles (called &ldquo;caf&eacute;-au-lait spots&rdquo;)",
"       </li>",
"       <li>",
"        Freckling of the skin in the armpits and in the crease where the legs meet the body",
"       </li>",
"       <li>",
"        Spots on the colored part of the eye that look like tiny freckles",
"       </li>",
"       <li>",
"        Problems with the way bones form, which can cause:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Bumps along the arms or legs that look like joints but aren&rsquo;t",
"       </li>",
"       <li>",
"        Deformed body parts (including the face)",
"       </li>",
"       <li>",
"        A curved spine or backbone (called &ldquo;scoliosis&rdquo;)",
"       </li>",
"       <li>",
"        Bones that break easily",
"       </li>",
"       <li>",
"        Short height for age",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      NF1 can also cause tumors to form inside the brain, around the nerves that connect the brain to the eye, and in other parts of the body. Some of these tumors can become cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518130\">",
"      <span class=\"h1\">",
"       Should I take my child to see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child develops any of the signs or symptoms listed above, take him or her to see the doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518145\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If the doctor or nurse suspects your child has NF1, he or she will do an exam and ask you questions. Doctors can diagnose NF1 based on the results of the exam.",
"     </p>",
"     <p>",
"      There is a blood test to check for the genetic problem that causes NF1. But doctors can diagnose NF1 without that test, so it is not always needed. If your child does have the genetic test, keep in mind that a child can have the genetic problem that causes NF1 but have only mild symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518160\">",
"      <span class=\"h1\">",
"       How is NF1 treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most important part of treatment involves checking for changes that could mean NF1 is causing problems. Children with NF1 must see the doctor at least once a year and have certain tests (",
"      <a class=\"graphic graphic_table graphicRef87043 \" href=\"UTD.htm?26/23/27004\">",
"       table 1",
"      </a>",
"      ). If NF1 starts causing certain problems, those problems must be treated. For example, if a skin growth gets too big or starts causing pain, surgery can be done to remove the growth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518192\">",
"      <span class=\"h1\">",
"       What if my child wants to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is a chance your child would have children with the same problem. When your child grows up, he or she should talk to a doctor to find out what the risks might be.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18518207\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child will need medical care throughout his or her life. It&rsquo;s best if he or she is treated by a team of experts who have experience with NF1. As your child ages, he or she will probably develop more neurofibromas and other health problems caused by NF1. Many of these problems can be dealt with, but some are very serious.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/41/26257?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87115 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26257=[""].join("\n");
var outline_f25_41_26257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518100\">",
"      What is neurofibromatosis type 1?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518115\">",
"      What are the signs and symptoms of NF1?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518130\">",
"      Should I take my child to see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518145\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518160\">",
"      How is NF1 treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518192\">",
"      What if my child wants to have children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18518207\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/23/27004\">",
"      How doctors monitor NF1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26258="Patient information: Hepatitis B (The Basics)";
var content_f25_41_26258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15382\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/34/25122\">",
"         Patient information: Liver transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/45/31447\">",
"         Patient information: Hepatitis B (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hepatitis B (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hepatitis-b-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H34079308\">",
"      <span class=\"h1\">",
"       What is hepatitis B?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hepatitis B is a serious disease that harms the liver. The liver is a big organ in the upper right side of the belly (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ). A virus causes this disease. The virus spreads from person to person when their bodily fluids touch. This can happen in a few ways, like having sex or sharing needles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079315\">",
"      <span class=\"h1\">",
"       What are the symptoms of hepatitis B?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people first get hepatitis B, they can feel like they have the flu. Some people&rsquo;s eyes or skin turn yellow (called jaundice). These symptoms usually get better, but it can take weeks to months.",
"     </p>",
"     <p>",
"      About 1 out of every 20 adults who gets hepatitis B ends up having the disease for a long time. This is called &ldquo;chronic&rdquo; hepatitis B. Most people with chronic hepatitis B have no symptoms. But, over time, the infection can lead to a liver condition called cirrhosis. Symptoms of cirrhosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling in the belly and legs, and fluid buildup in the lungs",
"       </li>",
"       <li>",
"        Bruising or bleeding easily",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling full",
"       </li>",
"       <li>",
"        Confusion that can come on suddenly",
"       </li>",
"       <li>",
"        Coma",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Chronic hepatitis B also increases the risk of getting liver cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079322\">",
"      <span class=\"h1\">",
"       How did I get the disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few ways to catch the hepatitis B virus. All of them involve mixing bodily fluids with other people. You might have caught the disease by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having sex with someone who was infected",
"       </li>",
"       <li>",
"        Sharing drug needles with someone who was infected",
"       </li>",
"       <li>",
"        Using infected needles for tattooing, acupuncture, or piercings",
"       </li>",
"       <li>",
"        Sharing toothbrushes, razors, or other personal items with someone who was infected",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have hepatitis B and are pregnant, you can also pass the infection on to your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079329\">",
"      <span class=\"h1\">",
"       Is there a test for hepatitis B?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have hepatitis B, he or she will do a routine exam to check for other problems. But he or she will probably also order a blood test to check for the virus.",
"     </p>",
"     <p>",
"      Your doctor might also want to remove a small sample of your liver to see if it is damaged. This is called a &ldquo;biopsy.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079336\">",
"      <span class=\"h1\">",
"       How is hepatitis B treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For people who have chronic hepatitis B, treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that fight the virus. There are several types. Your doctor will choose the right one for you, based on your symptoms.",
"       </li>",
"       <li>",
"        A liver transplant. In severe cases, people with hepatitis B need a new liver.",
"       </li>",
"       <li>",
"        Having an ultrasound test every 6 months to make sure they are not developing liver cancer. An ultrasound creates pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079343\">",
"      <span class=\"h1\">",
"       Is there anything I can do to protect my liver?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid alcohol",
"       </li>",
"       <li>",
"        Get vaccinated for hepatitis A and other diseases, including the flu and pneumonia",
"       </li>",
"       <li>",
"        Ask your doctor or nurse before taking any over-the-counter pain medicines. (These medicines can sometimes damage the liver.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079350\">",
"      <span class=\"h1\">",
"       How can I avoid giving the disease to other people?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of spreading hepatitis B by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a latex condom during sex",
"       </li>",
"       <li>",
"        Telling sex partners that you have the disease",
"       </li>",
"       <li>",
"        Not sharing razors, toothbrushes, or anything that might have blood on it",
"       </li>",
"       <li>",
"        Not sharing needles or syringes",
"       </li>",
"       <li>",
"        Using bandages to cover cuts and open sores",
"       </li>",
"       <li>",
"        Making sure your family and close friends get tested and get the vaccine for hepatitis B",
"       </li>",
"       <li>",
"        Cleaning drops of your blood off of things with a mixture of bleach and water. For the mixture, use 9 times more water than bleach.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079357\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor or nurse first. If you are infected when you give birth, your baby should get a special shot right away. This shot helps protect your baby from infection. You might also need treatment with a medicine for several weeks before giving birth. Plus, your baby will get a vaccine shot at 1 or 2 months old, and another one at 6 months. A test between 9 and 18 months will show if the baby has the disease. If not, he or she will get another vaccine shot then.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079364\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with hepatitis B are able to live normal lives. It is still safe to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hug and kiss",
"       </li>",
"       <li>",
"        Share forks, spoons, and cups",
"       </li>",
"       <li>",
"        Sneeze and cough around other people",
"       </li>",
"       <li>",
"        Breastfeed",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H34079371\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25122?source=see_link\">",
"       Patient information: Liver transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       Patient information: Hepatitis B (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/41/26258?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15382 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26258=[""].join("\n");
var outline_f25_41_26258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079308\">",
"      What is hepatitis B?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079315\">",
"      What are the symptoms of hepatitis B?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079322\">",
"      How did I get the disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079329\">",
"      Is there a test for hepatitis B?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079336\">",
"      How is hepatitis B treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079343\">",
"      Is there anything I can do to protect my liver?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079350\">",
"      How can I avoid giving the disease to other people?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079357\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079364\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34079371\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25122?source=related_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26259="Mechanism of angulation of middle phalangeal shaft fractures";
var content_f25_41_26259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Mechanism of angulation of middle phalangeal shaft fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reduction of middle/proximal fractures is achieved by axial traction and reversing the effects of the deforming forces acting on the fracture. The deforming forces that act on the middle phalanx are the flexor digitorum superficialis (FDS) and the intrinsic tendons. Fractures proximal to the FDS insertion will have an apex dorsal angulation (A), whereas fractures distal to the FDS insertion will have an apex volar angulation (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26259=[""].join("\n");
var outline_f25_41_26259=null;
var title_f25_41_26260="Polyethylene glycol 3350: Pediatric drug information";
var content_f25_41_26260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol 3350: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=see_link\">",
"    see \"Polyethylene glycol 3350: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/55/9076?source=see_link\">",
"    see \"Polyethylene glycol 3350: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2295346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dulcolax Balance&reg; [OTC];",
"     </li>",
"     <li>",
"      MiraLAX&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5599448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Osmotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F5599457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=see_link\">",
"      see \"Polyethylene glycol 3350: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Occasional constipation: Dulcolax Balance&reg;, MiraLax&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;6 months: 0.5-1.5 g/kg daily (initial dose: 0.5 g/kg; titrate to effect); not to exceed 17 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Oral: 17 g (~1 heaping tablespoon) daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fecal impaction: &gt;3 years: 1-1.5 g/kg daily (maximum daily dose: 100 g) for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bowel preparation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;2 years: 1.5 g/kg/day (maximum daily dose: 100 g) for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Mix 17 g in 8 oz of clear liquid and administer the entire mixture every 10 minutes until 2 liters are consumed (start within 6 hours after administering 20 mg bisacodyl delayed-release tablets) (Wexner, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2295374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral: 17 g/dose (119 g, 238 g, 255 g, 510 g, 527 g, 850 g); 17 g/packet (10s, 14s, 30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax Balance&reg;: 17 g/dose (119 g, 238 g, 510 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MiraLAX&reg;: 17 g/dose (119 g, 238 g, 510 g); 17 g/packet (10s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2295348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5599505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dulcolax Balance&reg;, MiraLax&trade;: 17 g (dose may be measured using bottle cap) added to 4-8 ounces of beverage (cold, hot, or room temperature)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5599454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature before reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5599449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of occasional constipation (FDA approved in ages &ge;17 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2295345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MiraLax&reg; may be confused with Mirapex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Polyethylene glycol 3350 may be confused with polyethylene glycol electrolyte solution",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MiraLax may be confused with Murelax brand name for oxazepam [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2295363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, cramping, diarrhea, flatulence, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic shock (observed with PEG 6000)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5599451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polyethylene glycol or any component; GI obstruction, ileus, gastric retention, bowel perforation, toxic colitis, megacolon",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5599503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5599452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients with symptoms of bowel obstruction (nausea, vomiting, abdominal pain, or distension) prior to use. 1-3 days may be required to produce bowel movement. Prolonged, frequent, or excessive use may lead to electrolyte imbalance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2295353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2295354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted in animals or in humans.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5599506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5599455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An osmotic agent, polyethylene glycol 3350 causes water retention in the stool; increases stool frequency",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5599504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Produces bowel movement in 1-3 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9888126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/55/9076?source=see_link\">",
"      see \"Polyethylene glycol 3350: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consult healthcare provider prior to use if you have nausea, vomiting, abdominal pain, irritable bowel syndrome, kidney disease, or a sudden change in bowel habits for &gt;2 weeks. Discontinue use and consult healthcare provider if you have diarrhea or rectal bleeding. Discontinue use if abdominal pain, bloating, cramping, or nausea gets worse, or if need to use for &gt;1 week.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bell EA and Wall GC, \"Pediatric Constipation Therapy Using Guidelines and Polyethylene Glycol 3350,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(4):686-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/14990783/pubmed\" id=\"14990783\" target=\"_blank\">",
"        14990783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Candy D and Belsey J, \"Macrogol (Polyethylene Glycol) Laxatives in Children With Functional Constipation and Faecal Impaction: A Systematic Review,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2009, 94(2):156-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/19019885/pubmed\" id=\"19019885\" target=\"_blank\">",
"        19019885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Co-Minh HB, Demoly P, Guillot B, et al, \"Anaphylactic Shock After Oral Intake and Contact Urticaria Due to Polyethylene Glycols,\"",
"      <i>",
"       Allergy",
"      </i>",
"      , 2007, 62(1):92-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/17156356/pubmed\" id=\"17156356\" target=\"_blank\">",
"        17156356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loening-Baucke V, \"Prevalence, Symptoms and Outcome of Constipation in Infants and Toddlers,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2005, 146(3):359-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/15756220 /pubmed\" id=\"15756220 \" target=\"_blank\">",
"        15756220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loening-Baucke V, Krishna R, and Pashankar DS, \"Polyethylene Glycol 3350 Without Electrolytes for the Treatment of Functional Constipation in Infants and Toddlers,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2004, 39(5):536-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/15572895/pubmed\" id=\"15572895\" target=\"_blank\">",
"        15572895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michail S, Gendy E, Preud'Homme D, et al, \"Polyethylene Glycol for Constipation in Children Younger Than Eighteen Months Old,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2004, 39(2):197-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/15269628/pubmed\" id=\"15269628\" target=\"_blank\">",
"        15269628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, \"Evaluation and Treatment of Constipation in Children: Summary of Updated Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):405-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/16954970/pubmed\" id=\"16954970\" target=\"_blank\">",
"        16954970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nurko S, Youssef NN, Sabri M, et al, \"PEG3350 in the Treatment of Childhood Constipation: A Multicenter, Double-Blinded, Placebo-Controlled Trial,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2008, 153(2):254-61, 261.e1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/18534221 /pubmed\" id=\"18534221 \" target=\"_blank\">",
"        18534221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pashankar DS, Bishop WP, and Loening-Baucke V, \"Long-Term Efficacy of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children With and Without Encopresis,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 2003, 42(9):815-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/14686553/pubmed\" id=\"14686553\" target=\"_blank\">",
"        14686553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pashankar DS, Loening-Baucke V, and Bishop WP, \"Safety of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2003, 157(7):661-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/12860787/pubmed\" id=\"12860787\" target=\"_blank\">",
"        12860787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pashankar DS, Uc A, and Bishop WP, \"Polyethylene Glycol 3350 Without Electrolytes: A New Safe, Effective, and Palatable Bowel Preparation for Colonoscopy in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144(3):358-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/15001943 /pubmed\" id=\"15001943 \" target=\"_blank\">",
"        15001943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelham RW, Nix LC, Chavira RE, et al, \"Clinical Trial: Single- and Multiple-Dose Pharmacokinetics of Polyethylene Glycol (PEG-3350) in Healthy Young and Elderly Subjects,\"",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2008, 28(2):256-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/18462266/pubmed\" id=\"18462266\" target=\"_blank\">",
"        18462266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safder S, Demintieva Y, Rewalt M, et al, \"Stool Consistency and Stool Frequency are Excellent Clinical Markers for Adequate Colon Preparation After Polyethylene Glycol 3350 Cleansing Protocol: A Prospective Clinical Study in Children,\"",
"      <i>",
"       Gastrointest Endosc",
"      </i>",
"      , 2008, 68(6):1131-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/18950761 [/pubmed\" id=\"18950761 [\" target=\"_blank\">",
"        18950761 [",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Berg MM, van Rossum CH, de Lorijn F, et al, \"Functional Constipation in Infants: A Follow-Up Study,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2005, 147(5):700-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/16291368/pubmed\" id=\"16291368\" target=\"_blank\">",
"        16291368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Voskuijl W, de Lorijn F, Verwijs W, et al, \"PEG 3350 (Transipeg) Versus Lactulose in the Treatment of Childhood Functional Constipation: A Double Blind, Randomised, Controlled, Multicentre Trial,\"",
"      <i>",
"       Gut",
"      </i>",
"      , 2004, 53(11):1590-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/15479678/pubmed\" id=\"15479678\" target=\"_blank\">",
"        15479678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wexner SD, Beck DE, Baron TH, et al, \"A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force From the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),\"",
"      <i>",
"       Surg Endosc",
"      </i>",
"      , 2006, 20(7):1161.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/16799744/pubmed\" id=\"16799744\" target=\"_blank\">",
"        16799744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Youssef NN, Peters JM, Henderson W, et al, \"Dose Response of PEG 3350 for the Treatment of Childhood Fecal Impaction,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 141(3):410-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26260/abstract-text/12219064/pubmed\" id=\"12219064\" target=\"_blank\">",
"        12219064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13070 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26260=[""].join("\n");
var outline_f25_41_26260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599448\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599457\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295374\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295348\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599505\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599454\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599449\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295345\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295363\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599451\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599503\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599452\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299899\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222409\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295353\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2295354\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599506\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599455\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5599504\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9888126\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=related_link\">",
"      Polyethylene glycol 3350: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/55/9076?source=related_link\">",
"      Polyethylene glycol 3350: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26261="Belladonna and opium: Drug information";
var content_f25_41_26261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Belladonna and opium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/35/12852?source=see_link\">",
"    see \"Belladonna and opium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/42/41636?source=see_link\">",
"    see \"Belladonna and opium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid);",
"     </li>",
"     <li>",
"      Antispasmodic Agent, Urinary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain: Rectal: 1 suppository 1-2 times/day, up to 4 doses/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3025137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/42/41636?source=see_link\">",
"      see \"Belladonna and opium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain: Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppository: Belladonna extract 16.2 mg and opium 30 mg; belladonna extract 16.2 mg and opium 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F139441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Prior to rectal insertion, the finger and suppository should be moistened. Assist with ambulation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe pain associated with ureteral spasms not responsive to nonopioid analgesics and to space intervals between injections of opiates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       B&amp;O may be confused with beano&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central  nervous system: Dizziness, drowsiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, photophobia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to belladonna, opium, or any component of the formulation; glaucoma; severe renal or hepatic disease; bronchial asthma; respiratory depression; convulsive disorders; acute alcoholism; premature labor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atropine idiosyncrasy: Use with caution in patients with known idiosyncrasy to atropine or atropine-like compounds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of opiate drug abuse or acute alcoholism; potential for drug dependency exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia; may cause urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with myxedema; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid long-term use in this age group due to potent anticholinergic effects and uncertain effectiveness (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended for use in children &le;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Usual precautions of opiate agonist therapy should be observed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F139421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3025133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this product. Refer to Atropine and Morphine Sulfate monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F139430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3025135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if/how much morphine or atropine may be found in breast milk following rectal administration of this product. Refer to Atropine and Morphine Sulfate monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Belladonna Alkaloids-Opium Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.2-60 mg (12): $337.90",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The pharmacologically active agents present in the belladonna component are atropine and scopolamine. Atropine blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS causing a relaxation of smooth muscle and drying of secretions.  The principle agent in opium is morphine. Morphine binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption: Rectal absorption is dependent upon body hydration, not temperature",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26261/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/41/26261/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9077 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26261=[""].join("\n");
var outline_f25_41_26261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139439\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139427\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025137\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139428\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139411\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139395\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139441\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802611\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139412\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139437\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139415\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139399\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298823\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139421\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139407\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025133\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139430\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025135\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323010\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139398\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139414\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/35/12852?source=related_link\">",
"      Belladonna and opium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/42/41636?source=related_link\">",
"      Belladonna and opium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26262="Evaluation of proteinuria in children";
var content_f25_41_26262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of proteinuria in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Marie France Gagnadoux, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26262/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/41/26262/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria as a marker of renal disease has been well established. The dilemma that faces the primary care physician is to differentiate the child with transient or other benign forms of proteinuria from the child with proteinuria from renal disease.",
"   </p>",
"   <p>",
"    An overview of the evaluation of proteinuria in children will be presented here. Some related issues, including the mechanisms of proteinuria, are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CLASSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein excretion in the normal child is less than 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day or a total of 150 mg per day. In neonates, normal urinary protein excretion is higher, up to 300",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    because of reduced reabsorption of filtered proteins.",
"   </p>",
"   <p>",
"    Approximately one-half of normal protein excretion consists of proteins secreted by tubular epithelium, mostly Tamm-Horsfall protein (uromodulin). The other half consists of plasma proteins including albumin, which accounts for approximately 40 percent of the total urinary protein, and low molecular weight (LMW) proteins, such as beta-2 microglobulin and amino acids.",
"   </p>",
"   <p>",
"    The normally low rate of urinary protein excretion is due to two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restriction of the filtration of proteins across the glomerular capillary wall",
"     </li>",
"     <li>",
"      Reabsorption of freely filtered LMW proteins (less than 25,000 Daltons) by the proximal tubule",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormal protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein excretion in excess of 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day or 4",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per hour is considered abnormal in children. Nephrotic range proteinuria (heavy proteinuria) is defined as &ge;1000",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day or 40",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    There are three main mechanisms of increased protein excretion: glomerular, tubular, and overflow proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Glomerular proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular proteinuria is due to increased filtration of macromolecules (particularly albumin) across the glomerular capillary wall. This may arise because of anatomical or functional lesions.",
"   </p>",
"   <p>",
"    Glomerular proteinurias are a common cause of proteinuria in children. They may result from glomerular disease (most often minimal change disease) or from nonpathologic conditions such as fever, intensive exercise, and orthostatic (or postural) proteinuria, in which protein excretion is increased only in the upright position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tubular proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubular proteinuria, which is less frequent, results from increased excretion of LMW proteins such as beta-2-microglobulin, alpha-1-microglobulin, and retinol-binding protein. These molecules are normally filtered across the glomerulus and then largely reabsorbed in the proximal tubule. Interference with proximal tubular reabsorption, due to a variety of tubulointerstitial diseases, can lead to increased excretion of these smaller proteins.",
"   </p>",
"   <p>",
"    Tubular proteinuria often is associated with other defects in proximal tubular function, including glycosuria, proximal renal tubular acidosis with bicarbonate wasting, and phosphaturia. In Fanconi's syndrome, all four of these proximal tubular defects occur.",
"   </p>",
"   <p>",
"    As will be described below, only albumin is detected by the urine dipstick, while tubular proteinuria is not detected by screening dipstick urinalysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Overflow proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overflow proteinuria results from increased excretion of low molecular weight proteins due to marked overproduction of a particular protein to a level that exceeds tubular reabsorptive capacity. Overflow proteinuria is not observed in children; it is primarily observed in adults with a plasma cell dyscrasia (eg, multiple myeloma) who overproduce immunoglobulin light chains.",
"   </p>",
"   <p>",
"    As with tubular proteinuria, overflow proteinuria with low molecular proteins will",
"    <strong>",
"     not",
"    </strong>",
"    be detected by screening dipstick urinalysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF URINARY PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several tests available for the measurement of urinary protein. The most common test, the urine dipstick, and other tests such as the sulfosalicylic acid (SSA) test that detects all proteins, measure only the urine protein concentration and cannot be used to quantify protein excretion. A dilute urine, for example, will underestimate the degree of proteinuria, while a highly concentrated urine may have a protein concentration greater than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    but not be indicative of increased protein excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urine dipstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary dipstick measures albumin concentration via a colorimetric reaction between albumin and tetrabromophenol blue producing different shades of green according to the concentration of albumin in the sample.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Negative",
"     </li>",
"     <li>",
"      Trace &ndash; between 15 and 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      1+ &ndash; between 30 and 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      2+ &ndash; between 100 and 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      3+ &ndash; between 300 and 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      4+ &ndash; &gt;1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dipstick testing will",
"    <strong>",
"     not",
"    </strong>",
"    detect low molecular (LMW) weight proteins. False-positive results may be obtained in samples that are very alkaline or contaminated by antiseptic agents (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    or benzalkonium chloride) or iodinated radiocontrast agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the urine should not be tested for protein with the dipstick for at least 24 hours after a contrast study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sulfosalicylic acid test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the urine dipstick, sulfosalicylic acid (SSA) detects all proteins in the urine including the LMW proteins that are not detected by the dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/2\">",
"     2",
"    </a>",
"    ]. The SSA test is performed by mixing one part urine supernatant (eg, 2.5 mL) with three parts 3 percent SSA, followed by assessment of the degree of turbidity. This test is infrequently necessary in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Quantitative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with persistent dipstick-positive proteinuria must undergo a quantitative measurement of protein excretion, most commonly on a timed 24-hour urine collection. In children (except neonates), levels of urinary protein excretion higher than 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day (or 4",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per hour) are abnormal. Proteinuria of greater than 40",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per hour is considered heavy or in the nephrotic range.",
"   </p>",
"   <p>",
"    In very young children, it may be difficult to obtain accurately timed urine collections. An alternative method of quantitative assessment is measurement of the total",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio",
"    <span class=\"nowrap\">",
"     (Pr/Cr)",
"    </span>",
"    on a spot urine sample, preferably the first morning specimen (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The normal value for this ratio is &lt;0.2 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (&lt;20 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine) in children greater than 2 years of age and &lt;0.5 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (&lt;50 mg",
"    <span class=\"nowrap\">",
"     protein/mmol",
"    </span>",
"    creatinine) in infants and toddlers from 6 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Qualitative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A qualitative analysis of urinary proteins may be necessary to differentiate glomerular from tubular proteinuria. A selective measurement, by immunonephelometry of marker proteins that include beta-2 microglobulin, alpha-1-microglobulin, lysozyme and retinol-binding protein can distinguish glomerular from tubular proteinuria. In tubular proteinuria, these levels will be 10 to 100 times higher than normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     APPROACH TO THE CHILD WITH PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive dipstick for protein on a random urinalysis is common in children. General screening of normal school-age children and adolescents with a urine dipstick will be positive (defined as &ge;1+) in 5 to 10 percent. However, only 0.1 percent of children have persistent proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/5\">",
"     5",
"    </a>",
"    ]. It is this small subset of children who are at the highest risk for renal disease.",
"   </p>",
"   <p>",
"    Proteinuria in children presents in three ways: transient or intermittent; orthostatic; and persistent (",
"    <a class=\"graphic graphic_table graphicRef73973 \" href=\"UTD.htm?31/16/32012\">",
"     table 1",
"    </a>",
"    ). Transient and orthostatic proteinuria are benign conditions that require no further evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient proteinuria is the most common cause. It can be induced by a variety of factors including fever, exercise, stress, seizures, and hypovolemia.",
"     </li>",
"     <li>",
"      Orthostatic proteinuria is defined as increased protein excretion in the upright position which returns to",
"      <strong>",
"       normal",
"      </strong>",
"      when the patient is recumbent. It is a common cause of proteinuria, especially in adolescent boys [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/6\">",
"       6",
"      </a>",
"      ]. Long-term studies have documented the benign nature of this condition, with recorded normal renal function up to 50 years later [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/7\">",
"       7",
"      </a>",
"      ]. As will be described below, the diagnosis is established by a negative dipstick on the first morning voided specimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link\">",
"       \"Orthostatic (postural) proteinuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent proteinuria should be more fully evaluated for underlying renal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation begins with a thorough history and physical examination to determine the type of proteinuria. A urine sample collected during a febrile illness or after intensive physical exercise or a seizure suggests the possible presence of transient proteinuria. Other findings suggest underlying renal disease and persistent proteinuria; these include a change in urine volume or color, evidence of edema or increased blood pressure, recent streptococcal infection, a positive family history for renal disease, and hearing loss, which is most suggestive of Alport disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Asymptomatic child",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of the child with dipstick-positive proteinuria depends in part upon the presence or absence of symptoms. The following approach is consistent with the recommendations of the 2000 Pediatric Nephrology panel established at the National Kidney Foundation conference on Proteinuria, Albuminuria, Risk, Assessment, Detection and Elimination (PARADE) (",
"    <a class=\"graphic graphic_algorithm graphicRef62887 \" href=\"UTD.htm?30/26/31136\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the asymptomatic child with an incidentally discovered positive dipstick for proteinuria, the first step is to repeat the test since, as mentioned above, the great majority of such episodes are transient and do not reflect any renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/5\">",
"     5",
"    </a>",
"    ]. The simplest approach is to measure the",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    ratio on a first morning void obtained at home, and to send for urinalysis a second specimen obtained in the office. The parents should be instructed to have the child void before going to bed and to remain recumbent until the first morning sample is obtained. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Measurement of urinary protein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following findings may be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A normal",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      ratio on the first morning void and a normal urinalysis indicate transient proteinuria.",
"     </li>",
"     <li>",
"      A normal",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      ratio on the first morning void and dipstick-positive proteinuria on the second upright specimen indicate orthostatic proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=see_link\">",
"       \"Orthostatic (postural) proteinuria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the proteinuria is transient or orthostatic, the patient should have a repeat urinalysis on a first morning void in one year.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      ratio on the first morning void and a positive dipstick on the second specimen indicate persistent proteinuria that requires further evaluation, beginning with examination of the urine sediment, looking for other signs of glomerular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parenchymal disease such as hematuria, red cell casts, pyuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipiduria. Red cell casts are pathognomonic for the presence of glomerulonephritis. Based upon the particular findings, certain patterns on the urinalysis are suggestive of glomerulonephritis, nephrotic syndrome, or other renal parenchymal disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"       \"Differential diagnosis and evaluation of glomerular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urinalysis may also be suggestive of a urinary tract infection with pyuria, bacteriuria, and positive nitrites or leukocyte esterase along with mild proteinuria. Proteinuria in such children typically resolves with successful treatment of the infection. If the proteinuria persists after eradication of the infection, further work-up is indicated.",
"   </p>",
"   <p>",
"    Among children with persistent proteinuria, a complete history and physical examination should be reviewed, including measurement of the blood pressure. Initial laboratory evaluation includes renal function tests (blood urea nitrogen and creatinine), serum electrolytes, cholesterol, albumin, and total protein. Other tests such as renal ultrasound, serum complement levels (C3 and C4), antinuclear antibody (ANA), streptozyme testing, hepatitis B and C serology, and human immunodeficiency virus (HIV) testing should be considered based on the clinical setting. A voiding cystourethrogram should be considered if there is an abnormal ultrasound with scarring or a history of febrile urinary tract infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"     \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If this initial evaluation is normal, the urine dipstick should be repeated on at least two additional specimens. If these subsequent tests are negative for protein, the diagnosis is transient proteinuria.",
"   </p>",
"   <p>",
"    If the proteinuria persists or if any of the studies are abnormal, the patient should be referred to a pediatric nephrologist. At this point, urinary protein excretion should be quantified by a timed collection, if obtainable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Indications for renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of renal biopsy in a child with isolated asymptomatic persistent proteinuria is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/2\">",
"     2",
"    </a>",
"    ]. Many nephrologists recommend close monitoring for those children with urinary protein excretion below 500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day before considering a biopsy. Monitoring should include assessment of blood pressure, protein excretion, and renal function. If any of these parameters shows evidence of progressive disease, a renal biopsy should be performed to establish a diagnosis.",
"   </p>",
"   <p>",
"    There are limited data on the results of renal biopsy in such children.",
"   </p>",
"   <p>",
"    In a retrospective review of 53 Japanese children with persistent isolated proteinuria who underwent renal biopsy from 1976 to 1989, a significant glomerular disease was present in almost half of the patients (n = 25): 15 had focal segmental glomerulosclerosis (FSGS); four had IgA nephropathy, and three each had membranous nephropathy and diffuse mesangial proliferative glomerulonephritis without IgA deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent case series from the same institution, 52 children with asymptomatic persistent proteinuria underwent renal biopsy from 2000 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/9\">",
"     9",
"    </a>",
"    ]. The 29 patients with a urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/mg",
"    </span>",
"    were more likely to have significant glomerular findings that included 5 with FSGS, and 7 with IgA nephropathy. The remaining 17 patients had minor glomerular changes. In contrast, only one of the 15 patients with a urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    &lt;0.5",
"    <span class=\"nowrap\">",
"     mg/mg",
"    </span>",
"    had FSGS, and the rest had minor glomerular changes. The authors suggest that a renal biopsy should be considered in asymptomatic children with constant isolated proteinuria with a urine",
"    <span class=\"nowrap\">",
"     Pr/Cr",
"    </span>",
"    &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/mg.",
"    </span>",
"   </p>",
"   <p>",
"    In a report of 461 Korean children with an abnormal urinalysis detected by school screening, only nine patients had isolated persistent proteinuria with protein excretion &ge;2 g in a 24-hour collection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26262/abstract/10\">",
"     10",
"    </a>",
"    ]. Renal biopsy demonstrated changes consistent with minimal change disease in seven patients, and one case each of mesangial proliferative glomerulonephritis and membranous glomerulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Symptomatic child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations in the symptomatic child with proteinuria may be general and nonspecific (eg, fever, malaise, weight loss), non-urinary specific (rash, purpura, arthritis), or urinary specific (eg, edema, hypertension, renal insufficiency). The underlying disorder may be primarily renal in origin or secondary to a systemic process. Diagnostic categories include infections, rheumatologic and immunologic disorders, and primary and secondary glomerular and interstitial diseases of the kidney.",
"   </p>",
"   <p>",
"    The diagnosis may be evident and straightforward from the history and physical examination, or it may be more complicated, with a need for early referral to a nephrologist. The practitioner must ensure that children with significant disease are clearly identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with heavy proteinuria and periorbital or peripheral edema must be evaluated promptly for nephrotic syndrome. The major manifestations of nephrotic syndrome are heavy proteinuria (protein excretion &gt;1000",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day or spot urine",
"      <span class=\"nowrap\">",
"       Pr/Cr",
"      </span>",
"      ratio &gt;1.0), edema, serum albumin &lt;2.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      and hypercholesterolemia. Almost all such children have idiopathic nephrotic syndrome, and management decisions should be made in consultation with a pediatric nephrologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-nephrotic children with persistent proteinuria who present with hypertension, an abnormal urinalysis, or an elevated plasma creatinine concentration should be referred to a pediatric nephrologist for further evaluation and possible renal biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"       \"Differential diagnosis and evaluation of glomerular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with an abnormal ultrasound or history of febrile urinary tract infections, a voiding cystourethrogram should be considered if there is an abnormal ultrasound with scarring or a history of febrile urinary tract infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=see_link\">",
"       \"Presentation, diagnosis, and clinical course of vesicoureteral reflux\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate the child with transient or other benign forms of proteinuria from the child with proteinuria from renal disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary protein excretion in excess of 100",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day or 4",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per hour is considered abnormal in children. Nephrotic range proteinuria (heavy proteinuria) is defined as &ge;1000",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day or 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per hour, and is always indicative of renal disease. The three main mechanisms of increased protein excretion include increased protein filtration either due to glomerular disease or overflow proteinuria of low molecular weight (LMW) proteins, or decreased tubular reabsorption. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abnormal protein excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common screening test for proteinuria is urinary dipstick test that measures albumin concentration via a colorimetric reaction. It cannot be used to quantify protein excretion, and it does not detect LMW proteins.",
"     </li>",
"     <li>",
"      Children with persistent dipstick-positive proteinuria must undergo a quantitative measurement of protein excretion. Quantitative measurements include a timed 24-hour urine collection or measurement of the total",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio",
"      <span class=\"nowrap\">",
"       (mg/mg)",
"      </span>",
"      on a spot urine sample, preferably the first morning specimen (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Quantitative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both benign and serious conditions can cause proteinuria in children. Childhood proteinuria presents in three ways: transient or intermittent; orthostatic; and persistent (",
"      <a class=\"graphic graphic_table graphicRef73973 \" href=\"UTD.htm?31/16/32012\">",
"       table 1",
"      </a>",
"      ). Transient and orthostatic proteinuria are benign conditions that require no further evaluation. General screening of normal school-age children and adolescents with a urine dipstick will be positive (defined as &ge;1+) in 5 to 10 percent. However, only 0.1 percent of children have persistent proteinuria. It is this small subset of children who are at the highest risk for renal disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to the child with proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a child with persistent proteinuria begins with a thorough history and physical examination. Further evaluation is based on the clinical manifestations elicited by the history and physical examination. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Approach to the child with proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asymptomatic child &ndash; In the asymptomatic child, repeat testing for proteinuria is generally performed to determine whether the proteinuria is transient, orthostatic or persistent (",
"      <a class=\"graphic graphic_algorithm graphicRef62887 \" href=\"UTD.htm?30/26/31136\">",
"       algorithm 1",
"      </a>",
"      ). In patients with transient or orthostatic proteinuria, a repeat urinalysis on a first morning void should be obtained in one year. Further workup is warranted in children with persistent proteinuria including renal function tests, and serum electrolytes, cholesterol, albumin and total protein. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Asymptomatic child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic child &ndash; The evaluation is based on the clinical manifestations that may be general and nonspecific (eg, fever, malaise, weight loss), non-urinary specific (rash, purpura, arthritis), or urinary specific (eg, edema, hypertension, renal insufficiency). In some cases, the diagnosis is evident based on the clinical findings, whereas it may be more subtle and complicated in others requiring further testing or referral to a pediatric nephrologist. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Symptomatic child'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/1\">",
"      Morcos SK, el-Nahas AM, Brown P, Haylor J. Effect of iodinated water soluble contrast media on urinary protein assays. BMJ 1992; 305:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/2\">",
"      Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/3\">",
"      Houser M. Assessment of proteinuria using random urine samples. J Pediatr 1984; 104:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/4\">",
"      Houser MT, Jahn MF, Kobayashi A, Walburn J. Assessment of urinary protein excretion in the adolescent: effect of body position and exercise. J Pediatr 1986; 109:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/5\">",
"      Vehaskari VM, Rapola J. Isolated proteinuria: analysis of a school-age population. J Pediatr 1982; 101:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/6\">",
"      Brandt JR, Jacobs A, Raissy HH, et al. Orthostatic proteinuria and the spectrum of diurnal variability of urinary protein excretion in healthy children. Pediatr Nephrol 2010; 25:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/7\">",
"      Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 1981; 305:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/8\">",
"      Yoshikawa N, Kitagawa K, Ohta K, et al. Asymptomatic constant isolated proteinuria in children. J Pediatr 1991; 119:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/9\">",
"      Hama T, Nakanishi K, Shima Y, et al. Renal biopsy criterion in children with asymptomatic constant isolated proteinuria. Nephrol Dial Transplant 2012; 27:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26262/abstract/10\">",
"      Lee YM, Baek SY, Kim JH, et al. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. Acta Paediatr 2006; 95:849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6091 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26262=[""].join("\n");
var outline_f25_41_26262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormal protein excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Glomerular proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tubular proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Overflow proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEASUREMENT OF URINARY PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urine dipstick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sulfosalicylic acid test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Quantitative assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Qualitative assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      APPROACH TO THE CHILD WITH PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Asymptomatic child",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Indications for renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Symptomatic child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6091|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/26/31136\" title=\"algorithm 1\">",
"      Eval proteinuria children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6091|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/16/32012\" title=\"table 1\">",
"      Causes of proteinuria children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17655?source=related_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3242?source=related_link\">",
"      Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26263="Evaluation of a tick bite for possible Lyme disease";
var content_f25_41_26263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of a tick bite for possible Lyme disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26263/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/41/26263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is the most common tick-borne disease in the United States and Europe. It is a spirochetal infection caused by Borrelia species (B. burgdorferi in the United States, and primarily B. afzelii and B. garinii in Europe and Asia) and is transmitted by the bite of infected Ixodes ricinus complex ticks. Lyme disease can involve the skin, joints, nervous system, and heart. In the United States, Ixodes ticks can also transmit human granulocytic anaplasmosis and babesiosis. In Europe, they can also transmit tick-borne encephalitis virus.",
"   </p>",
"   <p>",
"    Ticks have three stages in their life cycle: larva, nymph, and adult. Lyme disease is most commonly transmitted by nymphal ticks, which are typically most active during the late spring and early summer in temperate regions. Adult ticks can also transmit Lyme disease, but this occurs less commonly because adult ticks are less likely to bite humans and because they are larger and thus more likely to be detected and removed promptly. Adult ticks are most active on warm days in the fall.",
"   </p>",
"   <p>",
"    Individuals at highest risk for Lyme disease are those who live in an endemic region and have occupational (eg, forestry and telephone line workers) or recreational (eg, hunting, camping, hiking, gardening, children playing in wooded areas) exposure to ticks (",
"    <a class=\"graphic graphic_figure graphicRef80168 \" href=\"UTD.htm?10/32/10757\">",
"     figure 1",
"    </a>",
"    ). However, in highly endemic areas, people may be at risk even in their yards, particularly where grassy areas and woodlands meet.",
"   </p>",
"   <p>",
"    The factors affecting transmission of Lyme disease, methods for tick removal, and indications for antibiotic prophylaxis following a tick bite are reviewed here. The epidemiology, microbiology, prevention, diagnosis, clinical manifestations, and treatment of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42342?source=see_link\">",
"     \"Microbiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asking the following questions can aid in the risk assessment for Lyme disease following a tick bite:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Was the tick a member of the Ixodes species?",
"     </li>",
"     <li>",
"      Was the tick a larval, nymphal or adult tick?",
"     </li>",
"     <li>",
"      Was the tick attached?",
"     </li>",
"     <li>",
"      How long was the tick attached?",
"     </li>",
"     <li>",
"      Was the tick engorged?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of these factors is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tick size and appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick size and appearance can be helpful clues for determining the risk of disease transmission, but the validity of this information is highly dependent upon the expertise of the person viewing the tick. Patients sometimes confuse tick bites with bites by other types of arthropods. As an example, in one study 6 percent of specimens submitted by clinicians for tick identification were actually arthropods (most commonly beetles and lice) rather than ticks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"     \"Insect bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nymphal Ixodes ticks are typically tiny and round (about the size of a poppy seed). Nymphal stages of the American dog tick, Dermacentor variabilis, rarely bite humans, and nymphal stages of the lone star tick, Amblyomma americanum, are larger in comparison to Ixodes ticks (",
"    <a class=\"graphic graphic_picture graphicRef53018 \" href=\"UTD.htm?17/9/17553\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68309 \" href=\"UTD.htm?39/6/40037\">",
"     figure 2",
"    </a>",
"    ). Amblyomma ticks are found primarily in southern and mid-Atlantic states (",
"    <a class=\"graphic graphic_figure graphicRef75053 \" href=\"UTD.htm?13/40/13959\">",
"     figure 3",
"    </a>",
"    ). The 10 states with the highest incidence of Lyme disease include Maryland, Delaware, Pennsylvania, New Jersey, New York, Connecticut, Rhode Island, and Massachusetts along the Atlantic seaboard, as well as Minnesota and Wisconsin in the upper Midwest. In recent years, the incidence of Lyme disease in the northern New England states of Maine, Vermont, and New Hampshire has increased rapidly (",
"    <a class=\"graphic graphic_figure graphicRef80168 \" href=\"UTD.htm?10/32/10757\">",
"     figure 1",
"    </a>",
"    ), (",
"    <a class=\"graphic graphic_table graphicRef82242 \" href=\"UTD.htm?19/36/20034\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Adult Ixodes scapularis are larger than nymphal forms. Unengorged adults are approximately 3 mm in length. Female Ixodes ticks are orange-reddish, with a dark brown oval-shaped structure called a scutum covering the superior portion of the dorsal surface (",
"    <a class=\"graphic graphic_picture graphicRef81981 \" href=\"UTD.htm?25/35/26175\">",
"     picture 2",
"    </a>",
"    ); in contrast, the dorsal surface of male Ixodes ticks is uniformly brown since the entire surface is covered by a large scutum (",
"    <a class=\"graphic graphic_figure graphicRef68309 \" href=\"UTD.htm?39/6/40037\">",
"     figure 2",
"    </a>",
"    ). Adult female Amblyomma americanum ticks have a solitary white spot on their back (the \"lone star\") (",
"    <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"     picture 3",
"    </a>",
"    ). Adult male A. americanum ticks have an interconnected ring of white markings (",
"    <a class=\"graphic graphic_figure graphicRef68309 \" href=\"UTD.htm?39/6/40037\">",
"     figure 2",
"    </a>",
"    ). Dermacentor and Amblyomma ticks are not vectors of Lyme disease, although the former can transmit Rocky Mountain spotted fever and the latter is the vector of human monocytic ehrlichiosis. Amblyomma ticks have also been implicated in STARI (Southern tick-associated rash illness), which causes an expanding skin lesion similar to erythema migrans (EM). Although an infectious agent is thought to be the cause of STARI, none has yet been conclusively identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. While the skin lesion of STARI is similar to the EM rash of Lyme disease, STARI is not known to have the later manifestations associated with Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=see_link\">",
"     \"Southern tick-associated rash illness (STARI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tick attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ticks that are feeding are firmly attached to the skin. A tiny, round tick that is walking on the skin surface or that is easily removed has not yet started the feeding process and is thus not capable of transmitting Lyme disease.",
"   </p>",
"   <p>",
"    The duration of tick attachment is important in assessing the risk of transmission of Lyme disease. Borrelia spp are rarely transmitted within the first 48 hours of tick attachment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. As an example, a study of Lyme disease prevention found that among subjects bitten by nymphal ticks in whom the duration of attachment could be estimated, the risk of Lyme disease was 25 percent if the tick had fed for 72 hours compared with 0 percent if the tick had fed for a shorter period [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4\">",
"     4",
"    </a>",
"    ]. A separate study found that the incidence of Lyme disease was significantly higher when the duration of attachment was at least 72 hours: 3 of 15 such patients (20 percent) developed Lyme disease, compared with 1 of 94 (1 percent) in whom the tick was attached for less than 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, the risk of Lyme disease transmission from a firmly attached but unengorged tick was only 1 percent in a trial that was performed in a Lyme-endemic area in which approximately 15 percent of ticks were infected with B. burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a biologic basis for the preceding observations. B. burgdorferi are restricted to the lumen of the tick gut in unfed Ixodes ticks. Blood enters the tick's midgut during feeding, and the number of spirochetes in this location subsequently increases. In one study of starved nymphal ticks, the initial mean count of spirochetes in the tick midgut was 496 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/9\">",
"     9",
"    </a>",
"    ]. After attaching to the host, this number grew with a doubling time of approximately 4 hours, reaching a mean of 7848 spirochetes per nymph after 15 hours of attachment.",
"   </p>",
"   <p>",
"    As feeding ticks become engorged with blood, they release their saliva into the bite wound. In the study cited above, spirochetes were restricted to the gut of the tick during the initial 36 hours of attachment; however, spirochetes migrated to the salivary glands after approximately 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time required for B. burgdorferi to migrate from the midgut to the salivary glands of the Ixodes tick contrasts with the much shorter time required for ticks of the same species to transmit the organisms that cause human granulocytic anaplasmosis (HGA, previously called human granulocyte ehrlichiosis; Anaplasma phagocytophilum) and babesiosis (Babesia microti). Babesia and Anaplasma spp are present in the tick's salivary glands before feeding has begun [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Thus, the duration of tick attachment is less important for the risk assessment of transmission of these diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=see_link\">",
"     \"Epidemiology and pathogenesis of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is often difficult to determine how long a tick has been attached, it may be helpful if the patient can remember a situation in which he or she could have acquired a tick bite (eg, a walk through the woods).",
"   </p>",
"   <p>",
"    Ticks detach and fall off after becoming engorged from a blood meal. Engorged ticks are larger and have a globular shape (",
"    <a class=\"graphic graphic_picture graphicRef53018 \" href=\"UTD.htm?17/9/17553\">",
"     picture 1",
"    </a>",
"    ). Thus, if a patient reports finding an engorged tick (on their body or in their home), the risk of disease transmission is probably higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an attached tick is detected, the first step involves tick removal. Selected patients who seek care after detecting an attached tick may receive antimicrobial prophylaxis if they meet specific criteria (",
"    <a class=\"graphic graphic_table graphicRef69071 \" href=\"UTD.htm?25/21/25947\">",
"     table 2",
"    </a>",
"    ). These issues are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tick removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using proper technique for tick removal is important. Several methods of tick removal have been advocated. A study that evaluated the use of forceps or protected fingers, or the application of petroleum jelly, fingernail polish, isopropyl alcohol, or a hot match, found that only the use of forceps or protected fingers resulted in the satisfactory removal of 29 adult American dog ticks without leaving the mouthparts in the host skin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proper technique for removal of the attached tick includes the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If available, use tweezers or small forceps to grasp the tick as close to the skin surface as possible. In the absence of tweezers, use paper or cloth to protect the fingers during tick extraction.",
"     </li>",
"     <li>",
"      Pull straight up gently but firmly, using steady pressure. Do not jerk or twist.",
"     </li>",
"     <li>",
"      Do not squeeze, crush, or puncture the body of the tick, since its fluids may contain infectious agents.",
"     </li>",
"     <li>",
"      Disinfect the skin thoroughly after removing the tick and wash hands with soap and water.",
"     </li>",
"     <li>",
"      If sections of the mouthparts of the tick remain in the skin, they should be left alone as they will normally be expelled spontaneously.",
"     </li>",
"     <li>",
"      After the tick removal and the skin cleansing, the person bitten (or the parents) should observe the area for the development of EM for up to 30 days following exposure. Components of tick saliva can cause transient erythema that should not be confused with EM.",
"     </li>",
"     <li>",
"      Since the tick usually needs to be attached for two to three days before transmission of the Lyme disease agent occurs, removal of the tick within this time frame often prevents the infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4-7\">",
"       4-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11674211\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy and rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis with a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has been demonstrated to be effective in patients who meet a specified set of criteria. The rationale for this approach is discussed here.",
"   </p>",
"   <p>",
"    The characteristic rash of Lyme disease, EM occurs in approximately 80 percent of patients infected with B. burgdorferi (",
"    <a class=\"graphic graphic_picture graphicRef81270 \" href=\"UTD.htm?10/10/10400\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57414 \" href=\"UTD.htm?0/35/575\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75337 \" href=\"UTD.htm?26/16/26883\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67424 \" href=\"UTD.htm?34/20/35140\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment at this early stage of illness results in complete resolution of symptoms in at least 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link&amp;anchor=H4#H4\">",
"     \"Lyme disease: Clinical manifestations in children\", section on 'Erythema migrans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians and patients have expressed concerns that treating only patients who show signs of illness will leave a subset of individuals with untreated subclinical disease. It has been hypothesized that such patients may then progress to more serious and difficult to treat sequelae. If this were true, then preemptive therapy or repeated serologic testing after a tick bite might be considered. However, two randomized controlled trials of antibiotic prophylaxis for Lyme disease in the United States found no evidence of seroconversion in a total of 869 asymptomatic individuals who had recent tick bites [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Follow-up of subjects enrolled in a Lyme vaccine trial showed asymptomatic seroconversion in up to 10 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these cases were not directly associated with an identified tick bite. &nbsp;",
"   </p>",
"   <p>",
"    Several studies have investigated the efficacy of giving antibiotics at the time of a tick bite to prevent Lyme disease. Three randomized, placebo-controlled trials found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    administered after a tick bite did not protect against the subsequent development of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/8,17,18\">",
"     8,17,18",
"    </a>",
"    ]. However, these trials were small (387, 56, and 184 patients, respectively), and all three were underpowered to demonstrate a significant effect of prophylactic therapy, given the low incidence of Lyme disease after a tick bite even in endemic areas. A meta-analysis of these three studies also failed to demonstrate a significant beneficial effect of antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent randomized, double-blind trial involving 482 patients residing in an endemic area from whom I. scapularis ticks had been removed within the previous 72 hours demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg orally as a single dose) was effective in preventing Lyme disease (0.4 versus 3.2 percent for placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4\">",
"     4",
"    </a>",
"    ]. Only engorged nymphal ticks transmitted the disease. However, doxycycline caused more adverse effects than placebo (30 versus 11 percent). The most common side effects of doxycycline were nausea and vomiting.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    prophylaxis was 87 percent in this trial, but the 95 percent confidence interval was wide (25 to 98 percent) because there were few cases of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4\">",
"     4",
"    </a>",
"    ]. Data from this trial suggest that it would be necessary to give doxycycline to approximately 40 people to prevent one case of Lyme disease; 125 people would need to be treated if the efficacy was at the lower end of the calculated confidence interval. These estimates were based on exposure to ticks in an area with a relatively high incidence of Lyme disease (Westchester County, New York, where the incidence of Lyme disease was 0.5 to 1.0 reported cases per 1000 persons per at the time of the study). In most areas of the United States, the risk of Lyme disease is much lower, and thus the benefit of prophylactic doxycycline would be correspondingly much lower as well.",
"   </p>",
"   <p>",
"    Other investigators used data from various studies to assess the cost-benefit analysis of antibiotic prophylaxis for Lyme disease following a tick bite [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/20\">",
"     20",
"    </a>",
"    ]. They concluded that prophylaxis would be warranted if the incidence of Lyme disease following a tick bite was 3.6 percent. In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    prophylaxis trial described above, the risk of Lyme disease in patients bitten by nymphal ticks was higher if the tick was at least partially engorged (10 percent) than if it appeared flat (0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, antibiotic prophylaxis may be cost-effective after removal of an engorged Ixodes tick in Lyme-endemic regions.",
"   </p>",
"   <p>",
"    A potential concern with antibiotic prophylaxis is that if it is not successful in eradicating the bacteria whether there will be changes in the course of infection that will make it difficult to diagnose Lyme disease or make it more resistant to subsequent treatment. There is currently no evidence to support this concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Approach to prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the Infectious Diseases Society of America (IDSA) guidelines that recommend antibiotic prophylaxis only in patients who meet",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef69071 \" href=\"UTD.htm?25/21/25947\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attached tick identified as an adult or nymphal Ixodes scapularis tick (deer tick).",
"     </li>",
"     <li>",
"      Tick is estimated to have been attached for &ge;36 hours (by degree of engorgement or time of exposure).",
"     </li>",
"     <li>",
"      Prophylaxis is begun within 72 hours of tick removal.",
"     </li>",
"     <li>",
"      Local rate of infection of ticks with B. burgdorferi is &ge;20 percent (these rates of infection have been shown to occur in parts of New England, parts of the mid-Atlantic States, and parts of Minnesota and Wisconsin).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is not contraindicated (ie, the patient is not &lt;8 years of age, pregnant, or lactating).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient meets all of these criteria, the recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is 200 mg for adults and 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum dose of 200 mg in children &ge;8 years, given as a single dose. It is important to note that this regimen has never been tested in children; this recommendation is extrapolated from experience in adults.",
"   </p>",
"   <p>",
"    Given the high rate of development of EM in patients who are infected with B. burgdorferi and the excellent outcomes with early therapy, observation of the tick bite site with treatment for Lyme disease if an EM rash develops is an acceptable alternative for patients who meet criteria for antibiotic prophylaxis. This approach may be preferred in some patients in endemic areas who have frequent tick exposures and therefore might meet criteria for prophylaxis on multiple occasions; such patients may wish to avoid repeated use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . The treatment of Lyme disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , the IDSA does",
"    <strong>",
"     not",
"    </strong>",
"    recommend prophylaxis with an alternate antibiotic for the following reasons: there are no data to support the efficacy of a short course of another antibiotic; longer courses of antibiotics may lead to adverse effects; standard antibiotic treatment is highly effective if Lyme disease actually occurs; and finally, the risk of developing a serious complication of Lyme disease after a recognized tick bite is extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26263/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be remembered that Lyme disease less often results from a recognized tick bite, since removal of the tick within two to three days of attachment usually prevents transmission of B. burgdorferi. More commonly, Lyme disease is transmitted by the unrecognized tick that feeds to repletion (about four to five days) and then falls off without the person knowing that he or she has been bitten.",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis should",
"    <strong>",
"     not",
"    </strong>",
"    replace other preventive measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgM antibodies to B. burgdorferi typically appear within one to two weeks following the appearance of signs and symptoms of Lyme disease. IgG antibodies usually appear within two to six weeks following the onset of EM. Thus, there is",
"    <strong>",
"     no",
"    </strong>",
"    utility in performing serologic testing for Borrelia spp at the time of the tick bite. The indications for serologic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of Lyme disease\", section on 'Approach to diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of Lyme disease\", section on 'Indications for serologic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1553471489\">",
"    <span class=\"h2\">",
"     Testing ticks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although testing of individual ticks recovered from patients for B. burgdorferi by polymerase chain reaction (PCR) is available commercially, most experts do not recommend testing of ticks since the results do not affect clinical management. If the tick has not been attached for at least 36 hours, it is unlikely to have transmitted disease and no prophylaxis should be offered, even if PCR is positive. If the tick has been attached for &ge;36 hours, then prophylaxis is recommended and a delay in initiation of prophylaxis while awaiting results of testing could be detrimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=see_link\">",
"       \"Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most infections with Borrelia species, which cause Lyme disease, are transmitted by a nymphal stage Ixodes species tick (",
"      <a class=\"graphic graphic_picture graphicRef53018 \" href=\"UTD.htm?17/9/17553\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68309 \" href=\"UTD.htm?39/6/40037\">",
"       figure 2",
"      </a>",
"      ). This immature stage of the tick is quite small. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B. burgdorferi is not usually transmitted within the first 48 to 72 hours of tick attachment. The likelihood of transmission is increased if the tick is engorged",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has been attached for at least 72 hours. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Tick attachment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ticks are best removed with tweezers or protected fingers, pulling straight up with even pressure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tick removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who meet",
"      <strong>",
"       all",
"      </strong>",
"      criteria for antibiotic prophylaxis be treated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The criteria for prophylaxis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Attached tick identified as an adult or nymphal Ixodes scapularis tick (deer tick)",
"     </li>",
"     <li>",
"      Tick is estimated to have been attached for &ge;36 hours (by degree of engorgement or time of exposure)",
"     </li>",
"     <li>",
"      Prophylaxis is begun within 72 hours of tick removal",
"     </li>",
"     <li>",
"      Local rate of infection of ticks with B. burgdorferi is &ge;20 percent (these rates of infection have been shown to occur in parts of New England, parts of the mid-Atlantic States, parts of Minnesota and Wisconsin)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is not contraindicated (ie, the patient is not &lt;8 years of age, pregnant, or lactating) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient meets",
"      <strong>",
"       all",
"      </strong>",
"      of the above criteria, the recommended dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      is 200 mg for adults and 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to a maximum dose of 200 mg in children &ge;8 years, given as a single dose. If the patient cannot take doxycycline, we do not recommend prophylaxis with an alternate antibiotic. A reasonable alternative for patients who meet criteria for prophylaxis but who prefer not to take antimicrobial prophylaxis is to observe the tick bite site and treat for Lyme disease if an erythema migrans (EM) rash develops. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients who do not meet the criteria for antibiotic prophylaxis be observed and treated only if signs or symptoms of Lyme disease (eg, EM) develop (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"       \"Treatment of Lyme disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      performing serologic testing for Lyme disease in patients who report a tick bite. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/1\">",
"      Falco RC, Fish D, D'Amico V. Accuracy of tick identification in a Lyme disease endemic area. JAMA 1998; 280:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/2\">",
"      Campbell GL, Paul WS, Schriefer ME, et al. Epidemiologic and diagnostic studies of patients with suspected early Lyme disease, Missouri, 1990-1993. J Infect Dis 1995; 172:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/3\">",
"      Wormser GP, Masters E, Liveris D, et al. Microbiologic evaluation of patients from Missouri with erythema migrans. Clin Infect Dis 2005; 40:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/4\">",
"      Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/5\">",
"      Piesman J, Maupin GO, Campos EG, Happ CM. Duration of adult female Ixodes dammini attachment and transmission of Borrelia burgdorferi, with description of a needle aspiration isolation method. J Infect Dis 1991; 163:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/6\">",
"      des Vignes F, Piesman J, Heffernan R, et al. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis 2001; 183:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/7\">",
"      Sood SK, Salzman MB, Johnson BJ, et al. Duration of tick attachment as a predictor of the risk of Lyme disease in an area in which Lyme disease is endemic. J Infect Dis 1997; 175:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/8\">",
"      Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/9\">",
"      De Silva AM, Fikrig E. Growth and migration of Borrelia burgdorferi in Ixodes ticks during blood feeding. Am J Trop Med Hyg 1995; 53:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/10\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/11\">",
"      Piesman J, Lewengrub S, Rudzinska MA, Spielman A. Babesia microti: prolonged survival of salavarian piroplasms in nymphal Ixodes dammini. Exp Parasitol 1987; 64:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/12\">",
"      Needham GR. Evaluation of five popular methods for tick removal. Pediatrics 1985; 75:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/13\">",
"      Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003; 348:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/14\">",
"      Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/15\">",
"      Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/16\">",
"      Steere AC, Sikand VK, Schoen RT, Nowakowski J. Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis 2003; 37:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/17\">",
"      Costello CM, Steere AC, Pinkerton RE, Feder HM Jr. A prospective study of tick bites in an endemic area for Lyme disease. J Infect Dis 1989; 159:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/18\">",
"      Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child 1993; 147:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/19\">",
"      Warshafsky S, Nowakowski J, Nadelman RB, et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996; 11:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26263/abstract/20\">",
"      Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. N Engl J Med 1992; 327:534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7916 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26263=[""].join("\n");
var outline_f25_41_26263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS AFFECTING TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tick size and appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tick attachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tick removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11674211\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy and rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Approach to prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1553471489\">",
"      Testing ticks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/32/10757\" title=\"figure 1\">",
"      Lyme disease map US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/6/40037\" title=\"figure 2\">",
"      Tick sizes and appearances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/40/13959\" title=\"figure 3\">",
"      Ixodes nymph populations in US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7916|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/9/17553\" title=\"picture 1\">",
"      Engorged tick comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/35/26175\" title=\"picture 2\">",
"      Adult female Ixodes tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23582\" title=\"picture 3\">",
"      Lone star tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/10/10400\" title=\"picture 4\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/575\" title=\"picture 5\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26883\" title=\"picture 6\">",
"      Erythema migrans multiple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/20/35140\" title=\"picture 7\">",
"      EM vesicular",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/36/20034\" title=\"table 1\">",
"      Annual Lyme disease rate by state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/21/25947\" title=\"table 2\">",
"      Criteria for prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=related_link\">",
"      Epidemiology and pathogenesis of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42342?source=related_link\">",
"      Microbiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/10/13474?source=related_link\">",
"      Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=related_link\">",
"      Prevention of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=related_link\">",
"      Southern tick-associated rash illness (STARI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26264="Negative pressure wound therapy";
var content_f25_41_26264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Negative pressure wound therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Mark Gestring, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26264/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/41/26264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy (NPWT), also called vacuum-assisted wound closure, refers to wound dressing systems that continuously or intermittently apply subatmospheric pressure to the surface of a wound. NPWT has become a popular treatment modality for the management of many acute and chronic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subatmospheric pressure has multiple beneficial effects on wound healing in animal models. However, clinical evidence of its superiority over conventional wound dressing techniques for all wound types has not been proven. The available randomized trials have significant heterogeneity in the nature of wounds treated and in primary and secondary end points, making rigorous comparisons difficult and limiting the ability to generalize their results.",
"   </p>",
"   <p>",
"    The general mechanism of action of NPWT, its clinical uses and contraindications, placement and management of the device, and efficacy in specific clinical applications will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEVICE AND PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially-available systems for negative pressure wound therapy (NPWT) include the vacuum-assisted closure (V.A.C.&trade; therapy) device (KCI, San Antonio, Texas) and the Chariker-Jeter&trade; wound sealing kit (Smith and Nephew PLC, London, UK). V.A.C.&trade; therapy is the most widely-studied system in randomized trials.",
"   </p>",
"   <p>",
"    NPWT systems consist of an open-pore polyurethane ether foam sponge, semiocclusive adhesive cover, fluid collection system, and suction pump [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"     2",
"    </a>",
"    ]. The following steps are involved in placing the device (",
"    <a class=\"graphic graphic_figure graphicRef50588 \" href=\"UTD.htm?23/21/23889\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foam sponge is trimmed to fit the size of the open wound and placed into the wound, taking care that the foam does not extend beyond the margin of the wound.",
"     </li>",
"     <li>",
"      The foam is then secured beneath an adhesive sheet. A hole is cut in the adhesive and a suction port (more than one may be used) with tubing placed; the tubing extends to a disposable collection canister.",
"     </li>",
"     <li>",
"      A portable pump is connected to the suction tubing. The pump applies -50 to -175 mmHg of continuous or intermittent suction, which reduces the volume of the foam by up to 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/3\">",
"       3",
"      </a>",
"      ]. The porous nature of the polyurethane foam evenly distributes subatmospheric pressure to the surface of the wound, and provides a conduit for fluid removal from the wound surface to the collection system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When fragile structures are present within the wound, they should be protected with an interposition layer placed beneath the foam. The interposition layer should slide easily over the tissue. Examples of materials used as interposition layers include mesh (eg, Vicryl&reg;) or petrolatum gauze [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dressing changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dressing and tubing are typically changed every 24 to 36 hours depending upon the clinical situation. The device is turned off and the semi-occlusive dressing is removed. The sponge is carefully removed. If it is adherent to the underlying granulation tissue, the sponge can be soaked with saline and allowed to sit for a few minutes before removal. If pain is excessive during sponge removal, the sponge can be soaked with topical Xylocaine without epinephrine, prior to its removal either directly or via the suction tubing (suction off) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"     2",
"    </a>",
"    ]. Pain is controlled more effectively when administered prior to the dressing change.",
"   </p>",
"   <p>",
"    Wounds treated with NPWT may become malodorous, and infection may be suspected; however, bacterial counts typically remain low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"     2",
"    </a>",
"    ]. Hydrotherapy at the time of dressing changes, or the placement of a silver-containing interposition layer (eg, Aquacel&reg; silver) can help reduce odor. Alternatively, NPWT can be withheld for a day or two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients do not complain of significant pain with NPWT between dressing changes. However, appropriate pain medication should be given as the need arises (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient training and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should receive training on how to use the device, and be comfortable managing the device at home. Patients should be monitored frequently in an appropriate care setting by a trained practitioner. The patient should be informed of the potential complications associated with the device, and of the necessity to seek medical assistance immediately if bleeding is observed. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy (NPWT) accelerates wound healing. Normal wound healing progresses through the following phases: hemostasis, inflammation, proliferation, and remodeling.",
"   </p>",
"   <p>",
"    Both systemic and local wound factors can contribute to delayed wound healing. Systemic factors (eg, poor nutrition, wound ischemia) should be identified and corrected to the extent that is possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local wound factors that interfere with normal healing include desiccation, tissue edema, excessive exudate, poor tissue apposition (eg, grafts and flaps), and wound infection. Stagnant fluid is associated with cytogenetic factors that impede wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/4-10\">",
"     4-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies have shown that subatmospheric pressure improves the local wound environment through both direct and indirect effects; these effects accelerate healing and reduce the time to wound closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Direct effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The semipermeable dressing of the negative pressure system maintains a moist and warm environment that is stable and more conducive to wound healing. The closed system generates a pressure gradient between the wound and suction canister that promotes fluid transport, first from the wound bed, and then from the interstitial space, reducing wound edema.",
"   </p>",
"   <p>",
"    The open porous structure of the foam transmits the negative pressure to the wound surface. The wound deforms, drawing the edges of the wound together and firmly apposing any skin grafts or flaps that are present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. The degree of tissue deformation depends upon the stiffness of the tissue; scar tissue has less mobility and will have less of a response. Tissue deformation is an important stimulus for tissue remodeling mediated at the cellular level [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Indirect effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative pressure wound therapy (NPWT) is associated with a variety of indirect effects that promote wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/11\">",
"     11",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased blood flow &mdash; Subatmospheric pressure increases blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/12,18-20\">",
"       12,18-20",
"      </a>",
"      ]. However, care must be taken, since excessive negative pressure (more than -175 mmHg) decreases blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diminished inflammatory response &mdash; Reductions in systemic (eg, interleukins, monocytes) and local mediators of inflammation have been demonstrated in experimental models [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/21\">",
"       21",
"      </a>",
"      ]. In humans, decreased matrix metalloproteinase activity has been documented in patients treated with NPWT [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Altered bacterial burden &mdash; A reduction in bacterial burden was noted during the first clinical experiments evaluating NPWT, but the results were variable in later studies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/12,23,24\">",
"       12,23,24",
"      </a>",
"      ]. In a randomized trial, for example, both increasing and decreasing bacterial loads were seen depending upon the initial culture result [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in wound biochemistry &mdash; Mechanical deformation alters the local environment through the process of mechanotransduction (conversion of mechanical stimulus into chemical activity). In vitro, stretch increases human fibroblast growth and migration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/17\">",
"       17",
"      </a>",
"      ]. In an animal wound closure model, NPWT increased collagen organization, and increased the expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/25\">",
"       25",
"      </a>",
"      ]. The rate of wound closure was significantly higher in the NPWT group compared to gauze controls at day seven (54 versus 43 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of negative pressure to assist in wound healing was first described in the management of soft tissue injury in association with open fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/26\">",
"     26",
"    </a>",
"    ]. The demonstration of beneficial effects in animal models spurred the development of the negative pressure wound systems that are widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/12,27\">",
"     12,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Negative pressure wound therapy (NPWT, also called vacuum-assisted wound closure) has been applied to a wide range of clinical situations, including the open abdomen, following surgical debridement of acute or chronic wounds (eg, orthopedic, necrotizing infection, pressure ulcer), diabetic foot ulcers, and reconstructive surgery (eg, burns, skin graft, muscle flap) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/1,28\">",
"     1,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to traditional wound care modalities, NPWT offers several clinical advantages compared to usual care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional therapy consists of moist saline dressings that are changed up to three times daily. If too much time elapses between dressing changes, the gauze may become painfully adherent and its removal may debride desirable granulation tissue as well as devitalized tissue. Much of the pain associated with wound care occurs during dressing changes. In contrast, NPWT dressings are changed once every two to three days and anticipated pain can be managed preemptively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Device and placement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Dressing changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared to other forms of wound dressing, NPWT is easier to tailor and maintain in position. Almost every configuration of wound including circumferential extremity wounds (ie, degloving injuries), and wounds located in proximity to orthopedic fixation frames can be managed with relative ease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. As a result, NPWT may allow less complex modes of reconstructive surgery. Complex wounds that required a pedicle flap may, after NPWT, be converted to a wound requiring a rotation flap or skin graft [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accelerated wound healing with NPWT significantly reduces the time to wound closure in diabetic patients, returning these patients to baseline more quickly and improving quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chronic wounds'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reduced complexity of subsequent reconstructive procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the patient's perspective, the main disadvantage of NPWT is the need to carry the portable pump.",
"   </p>",
"   <p>",
"    NPWT systems are more expensive than traditional wound dressings. However, the overall cost of wound care depends upon the frequency of dressing changes, need for skilled nursing care, and duration of treatment. Significant clinical reductions in time to wound closure would be needed to offset the increased cost of the device and special supplies for NPWT to be cost-effective, but data are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPWT should not be used when any of the following are present [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposed vital structures &mdash; NPWT, in the presence of exposed organs, blood vessels, or vascular grafts, increases the risk for tissue erosion, which can lead to enteric fistula or hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/14,34\">",
"       14,34",
"      </a>",
"      ]. NPWT is generally avoided until an intervening granulation layer or tissue flap or graft provides coverage. Although some clinicians report success using barrier dressings, caution is advised when implementing this practice. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Device and placement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ongoing infection &mdash; Active infection should be treated prior to using NPWT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"       \"Necrotizing soft tissue infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Devitalized tissue &mdash; Inadequate debridement with the presence of devitalized soft tissue or bone increases the risk for infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/14\">",
"       14",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Malignant tissue &mdash; As with normal tissues, growth of malignant tissue is promoted in the presence of subatmospheric pressure. Malignant tissue is also more friable and prone to bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/2,14\">",
"       2,14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bleeding'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Fragile skin &mdash; Patients with fragile skin due to age, chronic corticosteroid use, or collagen vascular disorder should not be treated with NPWT. Shearing forces at the wound margin can lead to skin avulsion and necrosis.",
"     </li>",
"     <li>",
"      Adhesive allergy &mdash; NPWT requires an adequate seal to maintain the applied suction. The adhesive cover typically overlaps the skin 4 to 5 cm with a significant amount of adhesive in contact with the patient's skin. Sensitive patients can develop shearing of the skin and bullae formation.",
"     </li>",
"     <li>",
"      Ischemic wounds &mdash; Although not absolutely contraindicated, no benefit has been demonstrated with the use of NPWT in patients with ischemic wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/11\">",
"       11",
"      </a>",
"      ]. The application of negative pressure to these wounds would be expected worsen tissue ischemia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chronic wounds'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overall efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple systematic reviews have sought to evaluate the efficacy of negative pressure wound therapy (NPWT), but none have reached definitive conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/3,28,35-42\">",
"     3,28,35-42",
"    </a>",
"    ]. The most rigorous of these reviews identified eight randomized trials that met three inclusion criteria: randomized, chronic wound, and specific endpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/35\">",
"     35",
"    </a>",
"    ]. NPWT was used to treat diabetic ulcers, pressure (decubitus) ulcers, or chronic lower extremity ulcers. The primary endpoints were one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time to complete healing",
"     </li>",
"     <li>",
"      Days to reach 50 percent of initial wound volume",
"     </li>",
"     <li>",
"      Percent reduction in wound surface area",
"     </li>",
"     <li>",
"      Percent decrease in wound length, width, depth or volume",
"     </li>",
"     <li>",
"      Days until ready for surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because only one study was available for each endpoint, comparisons could not be made. Even if a meta-analysis were able to be performed, the question of whether chronic (or acute) wounds of differing mechanisms in different patient populations should be compared to each other.",
"   </p>",
"   <p>",
"    Another approach evaluates the available data (observational and randomized trials) for a specific clinical situation such as wounds from acute injury (eg, trauma, burns, surgical debridement) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/28,38,39\">",
"     28,38,39",
"    </a>",
"    ], wounds in diabetic patients (eg, ulcers, postoperative wounds) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/36,41\">",
"     36,41",
"    </a>",
"    ], open abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/43\">",
"     43",
"    </a>",
"    ], and open sternum (eg, following debridement) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/40\">",
"     40",
"    </a>",
"    ]. Available trials are presented for these individual clinical situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute wounds are often traumatic, but can also be due to surgical debridement of infected or necrotic tissue. Management of necrotizing soft tissue infection requires extensive and repeated surgical debridement. The debrided regions often present a wound dressing challenge due to anatomic location (eg, Fournier's gangrene), the size of the tissue defect or the patient's body habitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H23#H23\">",
"     \"Necrotizing soft tissue infections\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The open wound that results is often substantial. For most patients, the question is generally when, not if, their wounds will heal. The time interval required until either secondary closure can be performed or healing by secondary intention occurs is variable and depends upon the size of the defect, and the patient's overall clinical status (eg, other injuries, nutrition, comorbidities).",
"   </p>",
"   <p>",
"    NPWT dressings can be applied immediately following operative debridement, which simplifies postoperative wound care. The ability of the foam and adhesive dressing to conform to almost any wound contour, shape, or size contributes to the success of NPWT, as detailed in case reports, in these complex wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. NPWT can also be used in conjunction with skin grafts or flaps, which are frequently needed to cover tissue defects. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Skin graft/flap fixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For acute open wounds, NPWT is associated with a reduced time to wound closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As an example, one trial randomly assigned 54 patients with open wounds to receive either NPWT or moist saline dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/24\">",
"     24",
"    </a>",
"    ]. The NPWT group had healthier-appearing wounds and significantly faster reduction of the wound surface area (3.8 versus 1.7 percent per day).",
"   </p>",
"   <p>",
"    NPWT has also been used to manage acute wounds resulting from lower extremity fasciotomy, degloving injury, open amputation, and complex traumatic wounds with exposed tendon, bone, or orthopedic hardware. These wounds are typically large and difficult to dress.",
"   </p>",
"   <p>",
"    In trauma patients, a systematic review of the literature did not identify any randomized trials; however, the available observational studies suggest that NPWT is safe and with an efficacy comparable to standard dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/39\">",
"     39",
"    </a>",
"    ]. The primary clinical advantage of NPWT in the trauma population is its ease of application, decreased number of dressing changes, and reduction in the complexity of subsequent reconstructive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/27,47-50\">",
"     27,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPWT may have a particular role in the treatment of burn wounds. Impairment of blood flow in the zone of stasis may lead to burn wound progression (ie, partial thickness burn becomes full thickness burn). In animal models, subatmospheric pressure increases burn wound perfusion and limits this progression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anecdotal case reports and small case series have reported NPWT in the treatment of acute burn wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/38,52,53\">",
"     38,52,53",
"    </a>",
"    ]. Two studies have looked at bilateral hand burns as a model: one hand is treated with conventional dressings and the other with NPWT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A significant clinical advantage of the NPWT group was the ability to position the hand without the need for additional splinting. These preliminary studies have demonstrated the safety and feasibility of NPWT in burn patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPWT may improve the healing of some types of chronic",
"    <span class=\"nowrap\">",
"     wounds/ulceration",
"    </span>",
"    provided that they are well vascularized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/30,39,54\">",
"     30,39,54",
"    </a>",
"    ]. Patients with extremity wounds and inadequate peripheral pulses should undergo noninvasive vascular testing to confirm adequate perfusion prior to instituting NPWT, especially patients with diabetes or other risk factors for peripheral artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous stasis ulcers are uncommonly confused with other types of chronic ulcers. While these ulcers are associated with significant wound edema and exudate, they are managed with local wound care and compression therapy. NPWT is",
"    <strong>",
"     not",
"    </strong>",
"    a part of routine management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with conventional dressing changes, NPWT reduces time to closure of diabetic foot ulcers and wounds resulting from diabetic foot surgery. In this population of patients, NPWT is also associated with shorter length of hospitalization, decreased complication rates, and reduced costs. The use of NPWT in the management of diabetic foot lesions is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three randomized trials have evaluated the use of NPWT as an adjunctive therapy for the management of pressure (decubitus) ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/30,31,55\">",
"     30,31,55",
"    </a>",
"    ]. No statistically significant differences were identified with respect to quantitative wound healing measures (eg, wound surface area reduction). However, NPWT improved patient comfort and was less labor intensive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=see_link\">",
"     \"Treatment of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Skin graft/flap fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPWT has been used instead of traditional bolstering methods to provide skin graft fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/28,57\">",
"     28,57",
"    </a>",
"    ]. The NPWT dressing distributes negative pressure uniformly over the surface of the fresh graft, immobilizing the graft with less chance of shearing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/58\">",
"     58",
"    </a>",
"    ]. Improved qualitative skin graft take and quantitative improvements in skin graft success (eg, reduced number of repeat grafts) have been described in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/47,49,59,60\">",
"     47,49,59,60",
"    </a>",
"    ] and two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the trials, 60 patients were randomly assigned to conventional bolster dressing or NPWT following split thickness skin graft [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/61\">",
"     61",
"    </a>",
"    ]. NPWT was associated with significant reduction in the loss of graft area (zero versus 4.5 cm(2) in the control group) and the median duration of hospitalization (13.5 versus 17 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Open abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal wall of patients undergoing exploration for severe abdominal trauma is frequently left open to facilitate second look operations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/43,63\">",
"     43,63",
"    </a>",
"    ]. Reopening the abdomen may also be needed in patients for whom there is a concern for abdominal compartment syndrome. In this patient population, NPWT improves the success of both early and late (&gt;9 days) fascial closure. A general discussion of the management of the open abdomen is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Open sternum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-sternotomy mediastinitis is an uncommon but devastating complication of cardiac surgery with high morbidity and with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/28\">",
"     28",
"    </a>",
"    ]. Management consists of aggressive debridement, antibiotics and wound care which may include the use of negative pressure wound therapy to manage the open wound while awaiting sternal closure. The use of negative pressure wound therapy in this population is discussed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14858?source=see_link&amp;anchor=H104698238#H104698238\">",
"     \"Surgical management of sternal wound complications\", section on 'Negative pressure wound therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPWT is generally safe and well tolerated. Complications are most likely to occur when NPWT is applied to patients whose wounds have devitalized tissue or exposed vital structures (eg, organs, blood vessels, vascular grafts). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is the most serious complication of NPWT and can occur in hospitals, long-term care facilities, and at home [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/34\">",
"     34",
"    </a>",
"    ]. Minor bleeding during dressing changes due to granulation tissue at the base of the wound is common and is best managed with firm pressure to the wound surface. Severe hemorrhage can occur during removal of foam that has become adherent to the granulation tissue below, especially in patients who are anticoagulated, or in patients with exposed vessels or vascular grafts. In patients with severe bleeding, direct pressure should be applied and emergency services contacted. Surgery may be needed to control bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection related to the use of NPWT is often due to prior wound infection that was inadequately controlled prior to initiating NPWT. When infection is suspected (eg, fever, erythema, cellulitis), the NPWT dressing in discontinued, the wound irrigated and debrided, wound cultures obtained, and empiric antibiotics initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Enterocutaneous fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scattered case reports suggest that NPWT may expedite control and closure of postoperative enterocutaneous fistula. However, NPWT is also more likely to cause enteric fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/64-68\">",
"     64-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative pressure wound therapy (NPWT), also called vacuum-assisted closure, is an adjunctive therapy used in the management of open wounds that applies subatmospheric pressure to the wound surface. The wound care system consists of an open-cell foam dressing, semiocclusive adhesive cover, fluid collection system and suction pump. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Device and placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPWT exerts its effect through direct and indirect effects of subatmospheric pressure. These effects include stabilization of the wound environment, increased blood flow and deformation of the wound. Deformation is a powerful stimulus for cellular processes that stimulate granulation tissue and accelerate wound healing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPWT has several advantages over traditional wound management, including simplification of wound care (primarily through a reduced number of dressing changes and ease of tailoring the dressing), accelerated wound healing, and reduction in the complexity of subsequent reconstructive procedures. &nbsp;(See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPWT has been utilized in the treatment of wounds from acute injury (eg, trauma, burns, surgical debridement), wounds in diabetic patients (eg, ulcers, postoperative wounds), open abdomen [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26264/abstract/43\">",
"       43",
"      </a>",
"      ], and open sternum (eg, following debridement). High quality data supporting the use of NPWT are available only for the management of diabetic foot wounds. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical applications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"       \"Management of diabetic foot lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend not using NPWT if perfusion to the wound is inadequate (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). NPWT can cause or worsen tissue ischemia. Other contraindications to negative pressure wound therapy include the presence of vital structures within the wound, including organs, blood vessels, or vascular grafts; ongoing infection (ie, cellulitis, osteomyelitis); devitalized tissue in the wound; malignancy in the wound; skin or tissue fragility; and adhesive allergy (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Contraindications'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/1\">",
"      Capobianco CM, Zgonis T. An overview of negative pressure wound therapy for the lower extremity. Clin Podiatr Med Surg 2009; 26:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/2\">",
"      Venturi ML, Attinger CE, Mesbahi AN, et al. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol 2005; 6:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/3\">",
"      Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg 2008; 95:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/4\">",
"      Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen 1993; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/5\">",
"      Banwell PE. Topical negative pressure therapy in wound care. J Wound Care 1999; 8:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/6\">",
"      Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/7\">",
"      Sapico FL, Ginunas VJ, Thornhill-Joynes M, et al. Quantitative microbiology of pressure sores in different stages of healing. Diagn Microbiol Infect Dis 1986; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/8\">",
"      Hunt TK. The physiology of wound healing. Ann Emerg Med 1988; 17:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/9\">",
"      Falanga V. Growth factors and chronic wounds: the need to understand the microenvironment. J Dermatol 1992; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/10\">",
"      Genecov DG, Schneider AM, Morykwas MJ, et al. A controlled subatmospheric pressure dressing increases the rate of skin graft donor site reepithelialization. Ann Plast Surg 1998; 40:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/11\">",
"      Orgill DP, Manders EK, Sumpio BE, et al. The mechanisms of action of vacuum assisted closure: more to learn. Surgery 2009; 146:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/12\">",
"      Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg 1997; 38:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/13\">",
"      Pollak AN. Use of negative pressure wound therapy with reticulated open cell foam for lower extremity trauma. J Orthop Trauma 2008; 22:S142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/14\">",
"      Whelan C, Stewart J, Schwartz BF. Mechanics of wound healing and importance of Vacuum Assisted Closure in urology. J Urol 2005; 173:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/15\">",
"      Scherer SS, Pietramaggiori G, Mathews JC, et al. The mechanism of action of the vacuum-assisted closure device. Plast Reconstr Surg 2008; 122:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/16\">",
"      Urschel JD, Scott PG, Williams HT. The effect of mechanical stress on soft and hard tissue repair; a review. Br J Plast Surg 1988; 41:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/17\">",
"      Nishimura K, Blume P, Ohgi S, Sumpio BE. Effect of different frequencies of tensile strain on human dermal fibroblast proliferation and survival. Wound Repair Regen 2007; 15:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/18\">",
"      Kairinos N, Voogd AM, Botha PH, et al. Negative-pressure wound therapy II: negative-pressure wound therapy and increased perfusion. Just an illusion? Plast Reconstr Surg 2009; 123:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/19\">",
"      Ichioka S, Watanabe H, Sekiya N, et al. A technique to visualize wound bed microcirculation and the acute effect of negative pressure. Wound Repair Regen 2008; 16:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/20\">",
"      Morykwas MJ, Faler BJ, Pearce DJ, Argenta LC. Effects of varying levels of subatmospheric pressure on the rate of granulation tissue formation in experimental wounds in swine. Ann Plast Surg 2001; 47:547.",
"     </a>",
"    </li>",
"    <li>",
"     Norbury, K. Vacuum-assisted closure therapy attenuates the inflammatory response in porcine acute wound healing model. Wounds 2007; 19:97. Available online at: www.woundsresearch.com/article/7180 (Accessed on June 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/22\">",
"      Greene AK, Puder M, Roy R, et al. Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg 2006; 56:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/23\">",
"      Mou&euml;s CM, van den Bemd GJ, Heule F, Hovius SE. Comparing conventional gauze therapy to vacuum-assisted closure wound therapy: a prospective randomised trial. J Plast Reconstr Aesthet Surg 2007; 60:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/24\">",
"      Mou&euml;s CM, Vos MC, van den Bemd GJ, et al. Bacterial load in relation to vacuum-assisted closure wound therapy: a prospective randomized trial. Wound Repair Regen 2004; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/25\">",
"      Jacobs S, Simhaee DA, Marsano A, et al. Efficacy and mechanisms of vacuum-assisted closure (VAC) therapy in promoting wound healing: a rodent model. J Plast Reconstr Aesthet Surg 2009; 62:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/26\">",
"      Fleischmann W, Strecker W, Bombelli M, Kinzl L. [Vacuum sealing as treatment of soft tissue damage in open fractures]. Unfallchirurg 1993; 96:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/27\">",
"      Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997; 38:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/28\">",
"      Bovill E, Banwell PE, Teot L, et al. Topical negative pressure wound therapy: a review of its role and guidelines for its use in the management of acute wounds. Int Wound J 2008; 5:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/29\">",
"      Braakenburg A, Obdeijn MC, Feitz R, et al. The clinical efficacy and cost effectiveness of the vacuum-assisted closure technique in the management of acute and chronic wounds: a randomized controlled trial. Plast Reconstr Surg 2006; 118:390.",
"     </a>",
"    </li>",
"    <li>",
"     Joseph, E, Hamori, CA, Bergman, S, et al. A prospective randomized trial of vacuum-assisted closure versus standard therapy of chronic non-healing wounds. Wounds 2000; 12:60. Available online at: www.medscape.com/viewarticle/407550 (Accessed on June 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/31\">",
"      Ford CN, Reinhard ER, Yeh D, et al. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers. Ann Plast Surg 2002; 49:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/32\">",
"      Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/33\">",
"      Sumpio BE, Allie DE, Horvath KA, et al. Role of negative pressure wound therapy in treating peripheral vascular graft infections. Vascular 2008; 16:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/34\">",
"      White RA, Miki RA, Kazmier P, Anglen JO. Vacuum-assisted closure complicated by erosion and hemorrhage of the anterior tibial artery. J Orthop Trauma 2005; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/35\">",
"      Ubbink DT, Westerbos SJ, Evans D, et al. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008; :CD001898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/36\">",
"      Noble-Bell G, Forbes A. A systematic review of the effectiveness of negative pressure wound therapy in the management of diabetes foot ulcers. Int Wound J 2008; 5:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/37\">",
"      Expert Working Group. Vacuum assisted closure: recommendations for use. A consensus document. Int Wound J 2008; 5 Suppl 4:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/38\">",
"      Wasiak J, Cleland H. Topical negative pressure (TNP) for partial thickness burns. Cochrane Database Syst Rev 2007; :CD006215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/39\">",
"      Kanakaris NK, Thanasas C, Keramaris N, et al. The efficacy of negative pressure wound therapy in the management of lower extremity trauma: review of clinical evidence. Injury 2007; 38 Suppl 5:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/40\">",
"      Sj&ouml;gren J, Malmsj&ouml; M, Gustafsson R, Ingemansson R. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg 2006; 30:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/41\">",
"      Pham CT, Middleton PF, Maddern GJ. The safety and efficacy of topical negative pressure in non-healing wounds: a systematic review. J Wound Care 2006; 15:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/42\">",
"      Mendonca DA, Papini R, Price PE. Negative-pressure wound therapy: a snapshot of the evidence. Int Wound J 2006; 3:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/43\">",
"      Stevens P. Vacuum-assisted closure of laparostomy wounds: a critical review of the literature. Int Wound J 2009; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/44\">",
"      Kirby JP, Fantus RJ, Ward S, et al. Novel uses of a negative-pressure wound care system. J Trauma 2002; 53:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/45\">",
"      Garner GB, Ware DN, Cocanour CS, et al. Vacuum-assisted wound closure provides early fascial reapproximation in trauma patients with open abdomens. Am J Surg 2001; 182:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/46\">",
"      Hofmann P, Friess P, Findeisen M, Tomcik P. [Case report of successful therapy of necrotizing fasciitis using a device of vacuum assisted closure]. Zentralbl Chir 2006; 131 Suppl 1:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/47\">",
"      Barendse-Hofmann MG, van Doorn L, Steenvoorde P. Circumferential application of VAC on a large degloving injury on the lower extremity. J Wound Care 2009; 18:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/48\">",
"      DeFranzo AJ, Argenta LC, Marks MW, et al. The use of vacuum-assisted closure therapy for the treatment of lower-extremity wounds with exposed bone. Plast Reconstr Surg 2001; 108:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/49\">",
"      DeFranzo AJ, Marks MW, Argenta LC, Genecov DG. Vacuum-assisted closure for the treatment of degloving injuries. Plast Reconstr Surg 1999; 104:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/50\">",
"      Meara JG, Guo L, Smith JD, et al. Vacuum-assisted closure in the treatment of degloving injuries. Ann Plast Surg 1999; 42:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/51\">",
"      Morykwas MJ, David LR, Schneider AM, et al. Use of subatmospheric pressure to prevent progression of partial-thickness burns in a swine model. J Burn Care Rehabil 1999; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/52\">",
"      Molnar, JA. Application of negative pressure wound therapy to thermal injury. Ostomy wound management 2004; 50 (4A Suppl):17S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/53\">",
"      Kamolz LP, Andel H, Haslik W, et al. Use of subatmospheric pressure therapy to prevent burn wound progression in human: first experiences. Burns 2004; 30:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/54\">",
"      Vuerstaek JD, Vainas T, Wuite J, et al. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. J Vasc Surg 2006; 44:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/55\">",
"      Wanner MB, Schwarzl F, Strub B, et al. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. Scand J Plast Reconstr Surg Hand Surg 2003; 37:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/56\">",
"      Mandal A. Role of topical negative pressure in pressure ulcer management. J Wound Care 2007; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/57\">",
"      Jeschke MG, Rose C, Angele P, et al. Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg 2004; 113:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/58\">",
"      Schneider AM, Morykwas MJ, Argenta LC. A new and reliable method of securing skin grafts to the difficult recipient bed. Plast Reconstr Surg 1998; 102:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/59\">",
"      Molnar JA, DeFranzo AJ, Marks MW. Single-stage approach to skin grafting the exposed skull. Plast Reconstr Surg 2000; 105:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/60\">",
"      Scherer LA, Shiver S, Chang M, et al. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg 2002; 137:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/61\">",
"      Llanos S, Danilla S, Barraza C, et al. Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial. Ann Surg 2006; 244:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/62\">",
"      Moisidis E, Heath T, Boorer C, et al. A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting. Plast Reconstr Surg 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/63\">",
"      Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/64\">",
"      Schecter WP, Hirshberg A, Chang DS, et al. Enteric fistulas: principles of management. J Am Coll Surg 2009; 209:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/65\">",
"      Cro C, George KJ, Donnelly J, et al. Vacuum assisted closure system in the management of enterocutaneous fistulae. Postgrad Med J 2002; 78:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/66\">",
"      Alvarez AA, Maxwell GL, Rodriguez GC. Vacuum-assisted closure for cutaneous gastrointestinal fistula management. Gynecol Oncol 2001; 80:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/67\">",
"      Rao M, Burke D, Finan PJ, Sagar PM. The use of vacuum-assisted closure of abdominal wounds: a word of caution. Colorectal Dis 2007; 9:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26264/abstract/68\">",
"      Fischer JE. A cautionary note: the use of vacuum-assisted closure systems in the treatment of gastrointestinal cutaneous fistula may be associated with higher mortality from subsequent fistula development. Am J Surg 2008; 196:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2881 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26264=[""].join("\n");
var outline_f25_41_26264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEVICE AND PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dressing changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pain management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient training and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Direct effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Indirect effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overall efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Skin graft/flap fixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Open abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Open sternum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Enterocutaneous fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2881|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/21/23889\" title=\"figure 1\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14858?source=related_link\">",
"      Surgical management of sternal wound complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37064?source=related_link\">",
"      Treatment of pressure ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26265="Treatment of progressive multiple sclerosis in adults";
var content_f25_41_26265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of progressive multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26265/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26265/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/41/26265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/41/26265/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/41/26265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults. The course of MS is variable. For some, MS is a disease with one or two acute neurologic episodes and no further evidence of disease activity. In others, it is a chronic, relapsing, or progressive disease with an unpredictable clinical course that may span 10 to 20 years, during which time neurologic disability accumulates.",
"   </p>",
"   <p>",
"    Treatment directed at the progressive phase of MS is typically more difficult than treatment of relapsing forms of MS. Immunosuppressive therapies such as total lymphoid radiation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 2-chlorodeoxyadenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , interferon, steroids, and intravenous immune globulin have shown at least some positive clinical effects in progressive disease. However, all of these nonspecific immunosuppressants suffer from the same basic defect; they may temporarily halt a rapidly progressive downhill course, but it is difficult or dangerous to employ them for more than a few months to a year or two. Thus, since MS is an illness of decades, not months, immunosuppressive therapy is only a temporary solution at best.",
"   </p>",
"   <p>",
"    This topic will discuss treatment of progressive forms of MS. The treatment of relapsing forms of MS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .) Management of comorbid symptoms is likewise discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures of disease progression and prognosis are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGRESSIVE MS TYPES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Secondary progressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary progressive MS (SPMS) begins as relapsing-remitting disease (RRMS), but it later changes so that the course becomes characterized by a steady deterioration in function, unrelated to acute attacks. Typically, the attack rate is also reduced when the secondary progressive stage is reached. This type of MS, which ultimately develops in approximately 80 percent of RRMS patients, causes the greatest amount of neurologic disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary progressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary progressive MS (PPMS) represents only about 10 percent of cases at onset and is characterized by a steady decline in function from onset with no acute",
"    <span class=\"nowrap\">",
"     attacks.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Progressive relapsing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive/relapsing",
"    MS (PRMS) begins with a progressive course, with occasional attacks superimposed upon the steadily progressive course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (titrated up to a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has been studied in both relapsing-remitting and chronic progressing multiple sclerosis (MS) since 1971. A meta-analysis of the results of five double-blind and two single-blind, randomized, controlled trials of azathioprine use in MS showed only a small difference after two years in favor of azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/1\">",
"     1",
"    </a>",
"    ]. The study concluded that the side-effect profile outweighs any small clinical gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    , a potent immunosuppressive agent useful in the treatment of hairy cell leukemia, was reported to be of benefit in a study of patients with chronic-progressive MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/2\">",
"     2",
"    </a>",
"    ]. In this one-year, double-blind trial, 48 matched pairs received four monthly courses of cladribine or placebo through a central venous catheter over a seven-day period. Seven out of 23 evaluable patients receiving placebo experienced a one point or more worsening in their Expanded Disability Status Scale (EDSS) score at one year, while only one of 24 patients receiving cladribine had worsened. Treated patients had improvement on disability scores, no increase in brain MRI lesions, and decreased cerebrospinal fluid (CSF) oligoclonal bands, while the placebo group experienced the opposite in all of these categories. Side effects included two cases of herpes zoster, a fatal case of hepatitis (not clearly related to the treatment), and persistently lowered CD4 counts.",
"   </p>",
"   <p>",
"    In a subsequent multi-center trial, 159 patients with progressive MS (30 percent of whom had primary progressive and the remainder secondary progressive disease) were randomly assigned to one of two doses of subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (0.07",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for five consecutive days every four weeks for either two or six cycles [total dose 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 2.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    respectively]) or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/3\">",
"     3",
"    </a>",
"    ]. There was no significant difference between the groups in terms of EDSS score during the course of the study. However, the results of MRI studies were significantly different between the treatment and placebo groups. At baseline, approximately 35 percent of patients in each group had enhanced T1 lesions on MRI; this remained unchanged in the placebo group, while decreasing to 10 and 6 percent in the low and high-dose treatment groups, respectively. The cladribine groups also had a 90 percent reduction in the mean number of enhanced T1 lesions at month six that persisted over 24 months of follow-up, while the placebo group had a 33 and 50 percent reduction at the sixth month and final evaluation, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    was generally well tolerated in this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/3\">",
"     3",
"    </a>",
"    ]. The high-dose group reported more cases of upper respiratory infection, pharyngitis, back pain, arthralgia, and skin disorder compared with the low-dose and placebo groups; no serious infections occurred. Dose-related decreases in the mean lymphocyte count occurred with cladribine therapy. A disadvantage of the subcutaneous method of administration is that the total lymphocyte and CD-4 counts, as measures of effectiveness, do not fall for a number of months and may remain low for months after discontinuing therapy.",
"   </p>",
"   <p>",
"    One explanation for the difference in outcome between these two studies in terms of the EDSS score is that the patients in the second study had relatively high EDSS scores at baseline (median score 6.0); the size and duration of the study were not powered to detect results in patients with this severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, a significant proportion had primary progressive disease, and this subgroup did not respond as favorably on MRI as the secondary progressive group.",
"   </p>",
"   <p>",
"    A third study of 159 patients with progressive MS (70 percent secondary progressive, 30 percent primary progressive) found that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    did not prevent brain atrophy compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, the change in brain volume did not correlate with other MRI measures of disease (eg, number and volume of enhancing lesions).",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    for relapsing-remitting MS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Cladribine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175132689\">",
"    <span class=\"h2\">",
"     Dalfampridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6725?source=see_link\">",
"     Dalfampridine",
"    </a>",
"    (4-aminopyridine; fampridine), a potassium channel blocker, may improve walking speed in some patients with MS. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=see_link&amp;anchor=H12#H12\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\", section on 'Dalfampridine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly bolus IV glucocorticoids, typically 1000 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , are used at many institutions for treatment of primary or secondary progressive MS alone or in combination with other immunomodulatory or immunosuppressive medications. In a trial of methylprednisolone in secondary progressive MS, 108 patients received intravenous methylprednisolone (either 500 mg or 10 mg) every eight weeks for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/5\">",
"     5",
"    </a>",
"    ]. Although there was no difference in the proportions of patients in each treatment group who experienced sustained progression of disability, the time to onset of sustained treatment failure was delayed in the high-dose group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has been used for the treatment of MS since the early 1980s in spite of conflicting data. An early study compared an induction course of cyclophosphamide with steroid treatment and found impressive differences; in retrospect, however, the patients were all in a rapidly progressive phase of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/6\">",
"     6",
"    </a>",
"    ]. By comparison, a Canadian study several years later found no effect from an induction course of cyclophosphamide; these patients and controls were more representative of the chronic progressive patients treated in other trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    appears to be most effective in patients younger than age 40 years, especially in those who have been in the progressive phase for less than one year. The drug is ineffective for primary progressive MS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens have been employed. One such regimen involves pulse cyclophosphamide outpatient treatment that is repeated every four weeks in the first year of treatment, every six weeks in the second year, and every eight weeks in the third year. The duration of treatment is limited by the risk of bladder cancer, which appears to rise with time and may depend upon the total accumulated drug dose. Cyclophosphamide is generally tapered by going to an every 10 to 12 week schedule for the fourth year and then discontinuing.",
"   </p>",
"   <p>",
"    Pulse therapy is initiated by giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 g IV followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    800",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV (rounded to the nearest 100 mg) over 30 minutes on the same day. The following cyclophosphamide dose is titrated to the white blood cell (WBC) count nadir that occurs between 8 and 14 days after treatment. The dose is increased by 200",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    each month until the subsequent WBC nadir is between 1500 to 2000 mm3, or by 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    if the cyclophosphamide dose has reached 1400",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    and the target WBC nadir has not been achieved. The maximum cyclophosphamide dose is 1600",
"    <span class=\"nowrap\">",
"     mg/m2.",
"    </span>",
"    The dose is reduced by 100 to 200",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    if the WBC nadir falls below 1500 mm3.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose is also modified by a WBC count drawn just prior to the schedule treatment. The established cyclophosphamide dose is given if the pretreatment WBC count is above 4000 mm3, but it is reduced to 75 percent of the established dose if the pretreatment WBC count is between 3000 and 4000 mm3, and it is reduced to 50 percent if the pretreatment WBC count is 2000 to 3000 mm3. No maintenance dose is given if the pretreatment WBC count is below 2000 mm3; a repeat WBC count one week later can be used to determine if the patient is eligible for another treatment.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    include nausea, vomiting, infection, scalp alopecia, gonadal suppression, menstrual irregularities, premature menopause, and hemorrhagic cystitis. Nausea and vomiting can usually be managed with antiemetics. Infection should be treated promptly with appropriate antibiotics, and urinalysis should be done with each treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is teratogenic and is considered a category D drug regarding pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). It is excreted in breast milk, and its use is contraindicated during breast feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large multicenter trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/8\">",
"     8",
"    </a>",
"    ] and a trial in London [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/9\">",
"     9",
"    </a>",
"    ] found that cyclosporine (at a mean dose of 7.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has a beneficial, though modest, effect in ameliorating clinical disease progression. However, its clinical utility is limited because of a narrow benefit-to-risk ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Glatiramer acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase 3 multicenter randomized controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    for PPMS enrolled 943 patients but was prematurely halted after the second preplanned interim analysis because there was no discernible treatment effect on the primary outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/10\">",
"     10",
"    </a>",
"    ]. An unexpected low rate of disability progression among study participants may have contributed to the negative results of the study.",
"   </p>",
"   <p>",
"    These data do not exclude the possibility that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    may be used in PPMS, since at the present time there is no approved treatment for PPMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of interferons has been well documented in patients with relapsing-remitting disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a 2009 systematic review identified only two randomized controlled trials of interferon beta for the treatment of primary progressive MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/11\">",
"     11",
"    </a>",
"    ]. One evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/12\">",
"     12",
"    </a>",
"    ], and the other",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/13\">",
"     13",
"    </a>",
"    ]. In the pooled analysis, with a total of 123 patients, interferon beta treatment did not reduce disability progression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence is conflicting for the effectiveness of interferons in patients with secondary progressive MS (SPMS). A 2012 systematic review identified five randomized placebo-controlled trials that evaluated either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    or interferon beta 1-b in over 3100 patients with SPMS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/14\">",
"     14",
"    </a>",
"    ]. In the pooled analysis of three trials with outcome data assessed at three years, interferon treatment did",
"    <strong>",
"     not",
"    </strong>",
"    significantly decrease the risk of sustained disability progression (relative risk [RR] 0.98, 95% CI 0.82-1.16). In contrast, data from four trials with three year outcome data showed that interferon treatment reduced the risk of having at least one relapse (RR 0.91, 95% CI 0.84-0.97).",
"   </p>",
"   <p>",
"    Results of the individual trials are reviewed in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Interferon beta-1b",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     Interferon beta-1b",
"    </a>",
"    treatment for SPMS has been studied in at least two major randomized, controlled trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a European study conducted at 32 centers, 718 patients with SPMS were randomly assigned to receive placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      every other day subcutaneously for up to three years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/15\">",
"       15",
"      </a>",
"      ]. There was a 22 percent relative reduction in the proportion of patients with progression in the interferon beta-1b group compared with placebo. The time to becoming wheelchair-bound was also significantly delayed in the treatment group, equivalent to 12 months (p&lt;0.01). The placebo group had a mean eight percent increase in MRI lesion volume compared with a 5 percent decrease in the interferon beta-1b group. The authors asserted that the positive effect of treatment was due to a true effect on progression and not merely to a reduction in relapses leading to an indirect reduction in disability. Whether this effect was due to suppression of an inflammatory process could not be answered directly.",
"      <br/>",
"      <br/>",
"      Side effects were manageable; 45 patients taking interferon beta-1b stopped because of adverse effects compared with 15 taking placebo, but twice as many stopped because of inefficacy of treatment in the placebo group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Side effects of interferons'",
"      </a>",
"      .) Neutralizing antibodies were seen in 28 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Neutralizing antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A North American study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      in SPMS found no effect on time to confirmed progression to disability, although significant benefit was shown on all other outcomes, including a reduction in clinical relapses, newly active MRI lesions, and accumulated burden of disease on T2-weighted MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason for the disparity for the primary outcome measure (progression to disability) in the European and North American trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    in SPMS was most likely due to differences in the baseline progression and ongoing disease activity in the two study populations. These differences were noted in a retrospective pooled analysis of data from the two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the trials had similar (but not identical) entry criteria and study designs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/18\">",
"     18",
"    </a>",
"    ], the European study included patients in an earlier phase of SPMS who were younger and had a slightly shorter duration of disease. In addition, the European study had patients with more active disease both before and during the trial period. This suggests that MS progression in the European study population was more closely related to the acute inflammatory component of the disease, the component thought to be most responsive to interferon treatment, leading to a significant impact of interferon therapy on disease progression in the European but not the North American population.",
"   </p>",
"   <p>",
"    The retrospective pooled overall risk reduction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    treatment for EDSS progression confirmed at six months was 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/17\">",
"     17",
"    </a>",
"    ], showing a modest effect across the two studies, although this effect was driven largely by the European study. For patients with at least one relapse or change in EDSS by &gt;1 in the two years prior to study entry, the pooled risk reduction was 30 to 40 percent. This suggests that interferon beta-1b treatment reduced the risk of disease progression in patients with active clinical disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Interferon beta-1a",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     Interferon beta-1a",
"    </a>",
"    treatment for SPMS has been studied in several randomized controlled trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Secondary Progressive Efficacy Clinical Trial of Recombinant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       Interferon beta-1a",
"      </a>",
"      in MS (SPECTRIMS) found similar results to the North American study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      , with no significant effect on disability progression but significant benefit for relapse-related outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/19\">",
"       19",
"      </a>",
"      ]. Subgroup analysis suggested that the maximal benefit occurred in women and in patients who were still experiencing relapses when treatment started. In the latter subgroup only, treatment with interferon beta-1a was associated with benefit for disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The International MS Secondary Progressive Avonex Controlled Trial (IMPACT) used the Multiple Sclerosis Functional Composite (MSFC) as the primary endpoint, rather than the Expanded Disability Status Scale (EDSS) favored by most other large MS clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/21\">",
"       21",
"      </a>",
"      ]. Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      was associated with modest benefit on the MSFC but not the EDSS; treatment benefit was seen for reduction in relapses as with the earlier trials.",
"     </li>",
"     <li>",
"      A trial employing low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      compared with placebo found no benefit for disease progression or relapses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional hope for immunomodulatory therapy in patients with secondary progressive MS was provided by an MRI study, which found that compared with placebo, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    for three years resulted in significant improvements in all MRI measures, particularly in patients with relapses in the two years before the study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trial data for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    and particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    suggest but do not establish that patients with SPMS who have an acute inflammatory component can benefit from treatment with interferons. These data have major implications for the treatment of MS, since secondary progressive disease is the single largest category of MS. The problem is finding clinical features that reliably identify patients who are likely to be treatment responders because of acute inflammatory disease, versus those who are likely to be nonresponders because of progressive disease occurring independent of overt inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/17\">",
"     17",
"    </a>",
"    ]. Pronounced disability progression or continuing superimposed relapses may be useful features to identify interferon treatment responders among patients with SPMS, although no prospective clinical trials have confirmed this hypothesis. Additional data may further clarify the appropriate use of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is a well-known immunomodulator used extensively in other conditions such as rheumatoid arthritis. The only high-quality randomized controlled trial evaluating oral methotrexate for progressive MS found a statistically nonsignificant trend toward improvement in symptoms and radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In that trial, 60 patients with chronic-progressive MS were randomized to receive either weekly low-dose oral methotrexate (7.5 mg) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/24\">",
"     24",
"    </a>",
"    ]. Methotrexate positively affected measures of upper extremity function such as the 9-Hole Peg Test and a Block-in Box Test; these tests are a sensitive measure of repeated use of digits. However, lower extremity function as measured by ambulation and disability scales were not affected. There was no clinically significant toxicity.",
"   </p>",
"   <p>",
"    The relatively low dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (7.5 mg weekly) studied in this trial is a potential explanation for the lack of clear benefit. Whether higher doses given intravenously or intrathecally would be more effective in MS is unclear. The safety of methotrexate has been established in patients receiving 20 mg subcutaneously weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    is an anthracycline analogue that is used as a chemotherapeutic agent for some cancers. Although a small randomized trial found that mitoxantrone is effective for patients with worsening relapsing-remitting or secondary progressive MS, the risk of cardiotoxicity and potential for the development of leukemia with mitoxantrone limit its utility.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    in MS is supported by the results of a single multicenter, observer-blind trial of 194 patients with worsening relapsing-remitting or secondary progressive MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients were randomly assigned to treatment with IV mitoxantrone (5",
"    <span class=\"nowrap\">",
"     mg/m^2",
"    </span>",
"    or 12",
"    <span class=\"nowrap\">",
"     mg/m^2)",
"    </span>",
"    or placebo every three months for two years. Treatment with mitoxantrone was associated with significant clinical benefits compared with placebo on multivariate analysis, reducing progression of disability and clinical exacerbations.",
"   </p>",
"   <p>",
"    A subsequent report from the same trial analyzed MRI data collected from a nonrandomized subgroup of 110 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast to the clinical benefits,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    treatment did",
"    <strong>",
"     not",
"    </strong>",
"    significantly reduce the primary MRI outcome measure, the number of scans with positive gadolinium enhancement at 12 and 24 months, compared with placebo.",
"   </p>",
"   <p>",
"    The risk of cardiotoxicity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    prevents prolonged usage. Mitoxantrone therapy also is associated with a risk of developing therapy-related acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In patients with MS treated with mitoxantrone, a systematic review published in 2010 estimated that the risks of developing systolic dysfunction, heart failure, and acute leukemia are 12, 0.4, and 0.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/32\">",
"     32",
"    </a>",
"    ]. In patients with cancer who were treated with mitoxantrone, the rate of heart failure is estimated to be approximately 3 percent.",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    is 12",
"    <span class=\"nowrap\">",
"     mg/m^2",
"    </span>",
"    by intravenous administration every three months up to a maximum cumulative lifetime dose of 140",
"    <span class=\"nowrap\">",
"     mg/m^2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/32\">",
"     32",
"    </a>",
"    ]. The left ventricular ejection fraction (LVEF) should be evaluated before initiating mitoxantrone and prior to each subsequent dose. Mitoxantrone should be discontinued if there is a clinically significant reduction in the LVEF or if the LVEF is &lt;50 percent. In addition, annual cardiac testing should continue after completion of mitoxantrone therapy because of concern for delayed cardiotoxicity.",
"   </p>",
"   <p>",
"    Guidelines from the American Academy of Neurology recommend that, because of its toxicity and the somewhat limited evidence of benefit,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    should be reserved for patients with rapidly advancing disease who have failed other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients older than age 50, those with long-standing disability, and those with substantial spinal cord atrophy may be less likely to respond to intense immunosuppression with agents such as mitoxantrone than patients without these characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Natalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    in the treatment of secondary progressive MS is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/35\">",
"     35",
"    </a>",
"    ], and the drug has not been studied in patients with primary progressive MS. The utility of natalizumab treatment for relapsing forms of MS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the randomized placebo-controlled OLYMPUS trial of 439 adults with PPMS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was not beneficial for prolonging time to confirmed disease progression, the primary outcome measure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/36\">",
"     36",
"    </a>",
"    ]. The rituximab group had a significantly lower increase in T2 lesion volume on brain MRI than those assigned to placebo, but brain volume loss was similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER IMMUNE MODULATING TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic stem cell transplantation (HSCT) has shown promise in patients with progressive forms of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/37-40\">",
"     37-40",
"    </a>",
"    ] and in those with refractory relapsing-remitting MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/38,39,41\">",
"     38,39,41",
"    </a>",
"    ]. In addition, mesenchymal stem cell therapy for MS is being explored [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2011 systematic review of autologous HSCT in patients with progressive MS refractory to conventional medical treatment, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In eight case series with 161 patients (most with secondary progressive MS), progression-free survival at median follow-up times of 24 to 42 months ranged from 33 to 95 percent. There was substantial heterogeneity among these studies, which appeared to be due mainly to the intensity of the immunoablative conditioning regimen employed prior to HSCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a meta-analysis, the estimated rate of progression-free survival for 102 patients receiving intermediate-intensity conditioning regimens (five studies with a median followup of 39 months) was 79 percent (95% CI 70&ndash;87 percent).",
"     </li>",
"     <li>",
"      In contrast, the estimated rate of progression-free survival for 61 patients receiving high-intensity regimens (three studies with a median followup of 24 months) was 45 percent (95% CI 27&ndash;65 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 15 studies that reported adverse events, the most frequent complications occurring within six months of autologous HSCT were fever, engraftment syndrome, enteritis, and transient neurologic deterioration.",
"     </li>",
"     <li>",
"      Among 13 case series with post-treatment follow-up, seven patients died from treatment-related causes, mainly infection, and six patients died from nontreatment-related causes, mainly disease progression. Overall mortality was approximately 3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transplant-related mortality was as high as 8 percent in older studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], but appears to be lower since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/37,44\">",
"     37,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger controlled trials are awaited to evaluate the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of autologous HSCT for the treatment of MS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     IVIG infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few clinical trials have studied intravenous immune globulin (IVIG) in progressive forms of MS, and these have shown little or no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind, placebo-controlled study of 67 patients with an apparently irreversible motor deficit found that IVIG (0.4",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      for five days, then single infusions every two weeks for three months) did not reverse established weakness in MS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A larger trial randomly assigned 318 patients with clinically definite secondary progressive MS to monthly IVIG or placebo for 27 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/49\">",
"       49",
"      </a>",
"      ]. There was no difference between the IVIG and placebo groups on any of the clinical outcome measures or in change in T2 lesion load on MRI scan over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based primarily on the latter study, treatment with IVIG for progressive MS cannot be recommended. IVIG has shown benefit for RRMS in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have shown no benefit of plasma exchange for progressive forms of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/7,50,51\">",
"     7,50,51",
"    </a>",
"    ]. Therefore, guidelines from the American Academy of Neurology state that plasmapheresis should not be offered for chronic progressive or secondary progressive MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/52\">",
"     52",
"    </a>",
"    ]. However, plasma exchange may have some benefit for patients with acute central nervous system inflammatory demyelinating disease who do not respond to steroid therapy. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of acute exacerbations of multiple sclerosis in adults\", section on 'Plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Total lymphoid irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total lymphoid irradiation (TLI) has potent immunosuppressive effects and has been found beneficial in patients with progressive MS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/53\">",
"     53",
"    </a>",
"    ]. The absolute lymphocyte count appears to be an indicator of therapeutic efficacy, with greater efficacy in patients with lower counts. Many patients developed recurrent disease progression after initial therapy, and a major limitation is that use of TLI may preclude the use of other treatments that affect the immune system at a later time if the patient reenters the progressive phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the efficacy of various treatments for multiple sclerosis (MS) is derived mainly from prospective clinical trials. However, clinical trials have generally found only limited or no effectiveness for the available treatments of patients with secondary and primary progressive MS. In addition, most trials did not last longer than two or three years and give only hints about long-term results of treatment. Furthermore, patients may differ markedly from those who have been treated in clinical trials.",
"   </p>",
"   <p>",
"    Despite these obstacles, therapeutic decisions must be made. Treatment should be individualized on the basis of disease progression as well as patient and physician preference. The following treatment paradigm incorporates recommendations from the American Academy of Neurology (AAN) guidelines on disease modifying therapy for MS published in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"     54",
"    </a>",
"    ]. Updated and supplemental information for AAN guidelines may be found online (",
"    <a class=\"external\" href=\"file://www.aan.com/go/practice/guidelines\">",
"     www.aan.com/go/practice/guidelines",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment recommendations differ between primary progressive MS (PPMS) and secondary progressive MS (SPMS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Secondary progressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have found modest benefit for some treatments for patients with SPMS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous glucocorticoid monthly pulses (typically 1000 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ) &mdash; The AAN guidelines conclude that glucocorticoid treatment has a short-term benefit on the speed of functional recovery in patients with acute attacks of MS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. However, there does not appear to be any long-term improvement in the degree of functional recovery from an attack following the use of glucocorticoids. It is possible that regular pulse glucocorticoids may be useful in the long-term management of patients with RRMS. In my view, the same may be true for patients with SPMS who experience acute attacks. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and glucocorticoid monthly pulses &mdash; According to the AAN guidelines, it is possible that younger patients with progressive MS may derive some benefit from pulse plus booster cyclophosphamide treatment. However, pulse cyclophosphamide treatment does not seem to alter the course of progressive MS (PPMS and SPMS). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      oral or subcutaneous, 7.5 to 20 mg per week, with or without monthly glucocorticoid pulses &mdash; The AAN guidelines conclude that, based on limited and somewhat ambiguous evidence from a single trial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/24\">",
"       24",
"      </a>",
"      ], it is possible that methotrexate favorably alters the disease course in patients with SPMS and PPMS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider addition of an interferon, if not currently prescribed &mdash; The AAN guidelines state that it is appropriate to consider interferon treatment for patients with SPMS who are still experiencing relapses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. The effectiveness of interferons in patients with SPMS but without relapses is uncertain. As noted above (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Interferons'",
"      </a>",
"      above), pronounced disease progression may be another clinical feature that identifies patients with SPMS who are likely to be interferon responders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Primary progressive",
"    </span>",
"    &nbsp;&mdash;&nbsp;All suggested treatments for PPMS are empiric, as no convincing clinical trial evidence of effectiveness has been found for disease modifying therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous glucocorticoid monthly pulses (typically 1000 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      , oral or subcutaneous, 7.5 to 20 mg per week, with or without monthly glucocorticoid pulses &mdash; The AAN guidelines conclude that, based on limited and somewhat ambiguous evidence from a single trial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/24\">",
"       24",
"      </a>",
"      ], it is possible that methotrexate favorably alters the disease course in patients with SPMS and PPMS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      intravenous or subcutaneous &mdash; The AAN guidelines conclude that cladribine reduces gadolinium enhancement on brain MRI scans in patients with both relapsing and progressive forms of MS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. Cladribine treatment does not, however, appear to alter favorably the course of the disease, either in terms of attack-rate or disease progression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cladribine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      &mdash; According to the AAN guidelines, it is possible that mitoxantrone has a beneficial effect on disease progression in MS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mitoxantrone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/1\">",
"      Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/2\">",
"      Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/3\">",
"      Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/4\">",
"      Filippi M, Rovaris M, Iannucci G, et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000; 55:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/5\">",
"      Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/6\">",
"      Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/7\">",
"      The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991; 337:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/8\">",
"      Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol 1990; 27:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/9\">",
"      Rudge P, Koetsier JC, Mertin J, et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/10\">",
"      Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/11\">",
"      Rojas JI, Romano M, Ciapponi A, et al. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev 2009; :CD006643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/12\">",
"      Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/13\">",
"      Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004; 10 Suppl 1:S62; discussion 62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/14\">",
"      La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012; 1:CD005181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/15\">",
"      Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/16\">",
"      Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/17\">",
"      Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/18\">",
"      Cohen JA, Antel JP. Does interferon beta help in secondary progressive MS? Neurology 2004; 63:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/19\">",
"      Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/20\">",
"      Hughes RA. Interferon beta 1a for secondary progressive multiple sclerosis. J Neurol Sci 2003; 206:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/21\">",
"      Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/22\">",
"      Andersen O, Elovaara I, F&auml;rkkil&auml; M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/23\">",
"      Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/24\">",
"      Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/25\">",
"      Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006; 12:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/26\">",
"      Olek MJ, Hohol MJ, Weiner HL. Methotrexate in the treatment of multiple sclerosis. Ann Neurol 1996; 39:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/27\">",
"      Hartung HP, Gonsette R, K&ouml;nig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/28\">",
"      Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005; 65:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/29\">",
"      Ramkumar B, Chadha MK, Barcos M, et al. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Cancer Genet Cytogenet 2008; 182:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/30\">",
"      Bosca I, Pascual AM, Casanova B, et al. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 2008; 71:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/31\">",
"      Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011; 77:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/32\">",
"      Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/33\">",
"      Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/34\">",
"      Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/35\">",
"      Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/36\">",
"      Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/37\">",
"      Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/38\">",
"      Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 2011; 76:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/39\">",
"      Mancardi GL, Sormani MP, Di Gioia M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012; 18:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/40\">",
"      Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010; 16:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/41\">",
"      Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/42\">",
"      Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011; 10:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/43\">",
"      Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/44\">",
"      Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 2011; 17:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/45\">",
"      Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004; 126:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/46\">",
"      Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol 2005; 128:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/47\">",
"      Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005; 45:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/48\">",
"      Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/49\">",
"      Hommes OR, S&oslash;rensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/50\">",
"      Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci 1985; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/51\">",
"      Khatri BO, McQuillen MP, Harrington GJ, et al. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/52\">",
"      Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.",
"     </a>",
"    </li>",
"    <li>",
"     Cook SD, Devereux C, Troiano R, et al. Total lympoid irradiation in multiple sclerosis. In: Treatment of multiple sclerosis: Trial design, results,a nd future perspectives, Rudick RA, Goodkin DE.  (Eds), Springer Verlag, New York 1992. p.267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/41/26265/abstract/54\">",
"      Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1686 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3A9BE56C6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26265=[""].join("\n");
var outline_f25_41_26265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGRESSIVE MS TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Secondary progressive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary progressive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Progressive relapsing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cladribine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175132689\">",
"      Dalfampridine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Glatiramer acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Interferon beta-1b",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Interferon beta-1a",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Natalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER IMMUNE MODULATING TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      IVIG infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Total lymphoid irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Secondary progressive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Primary progressive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1686|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=related_link\">",
"      Treatment of acute exacerbations of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_41_26266="RUL SPN PA";
var content_f25_41_26266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75774%7EPULM%2F55811%7EPULM%2F69851%7EPULM%2F58095%7EPULM%2F82372%7EPULM%2F59657%7EPULM%2F73552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75774%7EPULM%2F55811%7EPULM%2F69851%7EPULM%2F58095%7EPULM%2F82372%7EPULM%2F59657%7EPULM%2F73552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with right upper lobe solitary pulmonary nodule proven to be a lung cancer. Chest radiograph shows a faint opacity partially hidden by the head of the right clavicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal (left) and axial (right) PET scan demonstrate a glucose avid nodule in the right upper lobe without evidence for mediastinal lymph node involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with solitary pulmonary nodule in the right lung, suspicious for lung cancer but proven to represent a coccidioidal granuloma. Chest radiograph shows a subpleural nodule in the lateral segment of the right middle lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan confirms the location of the nodule in the lateral segment of the right middle lobe, abutting the major fissure and the parietal pleura. A small central lucency indicates incipient cavitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal PET scan shows only very weak uptake of radionuclide in this benign lesion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with solitary pulmonary nodule in the right lower lobe, proven to represent a lung cancer. CT scan shows the solitary lesion in the superior segment of the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal (left) and axial (right) PET scan confirm the solitary nature of the nodule and exclude mediastinal lymph node metastasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26266=[""].join("\n");
var outline_f25_41_26266=null;
var title_f25_41_26267="Tx of hypoparathyroidism";
var content_f25_41_26267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hypoparathyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Treatment",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Calcium",
"      </td>",
"      <td>",
"       1.0-1.5 g elemental daily (total diet + supplement) in divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adjust dose as needed to control symptoms and maintain low-normal serum calcium concentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Vitamin D",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Calcitriol",
"      </td>",
"      <td>",
"       0.5-1.0 micgrograms daily (in divided doses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Alfacalcidol",
"      </td>",
"      <td>",
"       0.5-2.0 micrograms daily (in divided doses)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ergocalciferol (D2)",
"      </td>",
"      <td rowspan=\"2\">",
"       25,000-100,000 International Units daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cholecalciferol (D3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dihydrotachysterol",
"      </td>",
"      <td>",
"       0.2-1.2 mg daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thiazide diuretics (if required to control hypercalciuria)",
"      </td>",
"      <td>",
"       25-100 mg daily",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Goltzman, D, Cole, DEC. Hypoparathyroidism. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society of Bone and Mineral Research 2006; 6:216.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26267=[""].join("\n");
var outline_f25_41_26267=null;
var title_f25_41_26268="Pregnancy outcomes in women with mitral stenosis";
var content_f25_41_26268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of pregnancy outcomes in women with mitral stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Severity of MS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of pregnancies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Congestive heart failure or pulmonary edema",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arrhythmia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preterm delivery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Small for gestational age or intrauterine growth restriction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Still birth or fetoneonatal death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        20 percent",
"       </td>",
"       <td class=\"centered\">",
"        8 percent",
"       </td>",
"       <td class=\"centered\">",
"        11 percent",
"       </td>",
"       <td class=\"centered\">",
"        8 percent",
"       </td>",
"       <td class=\"centered\">",
"        2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td class=\"centered\">",
"        47",
"       </td>",
"       <td class=\"centered\">",
"        45 percent",
"       </td>",
"       <td class=\"centered\">",
"        15 percent",
"       </td>",
"       <td class=\"centered\">",
"        27 percent",
"       </td>",
"       <td class=\"centered\">",
"        19 percent",
"       </td>",
"       <td class=\"centered\">",
"        2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"       <td class=\"centered\">",
"        67 percent",
"       </td>",
"       <td class=\"centered\">",
"        33 percent",
"       </td>",
"       <td class=\"centered\">",
"        39 percent",
"       </td>",
"       <td class=\"centered\">",
"        17 percent",
"       </td>",
"       <td class=\"centered\">",
"        11 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Overall",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         <strong>",
"          126",
"         </strong>",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         36 percent",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         14 percent",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         21 percent",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         13 percent",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         3 percent",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001; 37:89",
"      </li>",
"      <li>",
"       Silversides CK, Colman JM, Sermer M, Siu SC. Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol 2003; 91:1382.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26268=[""].join("\n");
var outline_f25_41_26268=null;
var title_f25_41_26269="Immunohistochemical staining of cutaneous tumors";
var content_f25_41_26269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunohistochemical staining of select cutaneous tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"10\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        &gt;25 percent p53",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ki 67",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ber EP4",
"       </td>",
"       <td class=\"subtitle1\">",
"        p63",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        CEA",
"       </td>",
"       <td class=\"subtitle1\">",
"        AE14",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        CK 20",
"       </td>",
"       <td class=\"subtitle1\">",
"        CK 15",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        CK 7",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         MAC",
"        </strong>",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"       <td>",
"        &lt;5 percent",
"       </td>",
"       <td>",
"        <p>",
"         0 percent",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        38 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Peripheral staining 100 percent",
"       </td>",
"       <td>",
"        50 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        <br/>",
"        54 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [4,6]",
"        </sup>",
"       </td>",
"       <td>",
"        92 percent",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         BCC",
"        </strong>",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"       <td>",
"        20 to 40 percent",
"       </td>",
"       <td>",
"        <p>",
"         100 percent",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        100 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Diffuse 100 percent",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [3,4]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [4,6]",
"        </sup>",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        40 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         DTE",
"        </strong>",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        <p>",
"         75 percent",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        50 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        Diffuse 100 percent",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [3,4]",
"        </sup>",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        <p>",
"         12 percent",
"         <sup>",
"          [4]",
"         </sup>",
"        </p>",
"        100 percent",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Syringoma",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        100 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        33 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SCC",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        38 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0 percent",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        12 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MAC: microcystic adnexal carcinoma; BCC: basal cell carcinoma; DTE: desmoplastic trichoepithelioma; SCC: squamous cell carcinoma.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Smith KL, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: An immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol 2001; 25:464.",
"       </li>",
"       <li>",
"        Vidal CI, Goldberg M, Burstein DE, et al. p63 Immunohistochemistry is a useful adjunct in distinguishing sclerosing cutaneous tumors. Am J Dermatopathol 2010; 32:257.",
"       </li>",
"       <li>",
"        Wick MR, Cooper PH, Swanson PE, et al. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol 1990; 126:189.",
"       </li>",
"       <li>",
"        Hoang MP, Dresser KA, Kapur P, et al. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol 2008; 21:178.",
"       </li>",
"       <li>",
"        Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol 2007; 34:782.",
"       </li>",
"       <li>",
"        Abesamis-Cubillan E, El-Shabrawi-Caelen L, Leboit PE. Merked cells and sclerosing epithelial neoplasms. Am J Dermatopathol 2000; 22:311.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26269=[""].join("\n");
var outline_f25_41_26269=null;
var title_f25_41_26270="Decreased survival in RA";
var content_f25_41_26270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Decreased survival in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival curves for 905 patients with RA in Saskatoon, Canada compared with data from the general Canadian population. The death rate is increased throughout the course of RA with a tendency to accelerate after 15 years of follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wolfe, F, Mitchell, DM, Sibley, JT, et al, Arthritis Rheum 1994; 37:481.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26270=[""].join("\n");
var outline_f25_41_26270=null;
var title_f25_41_26271="Oblique view of fifth metatarsal fracture nonunion";
var content_f25_41_26271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique view of a fifth metatarsal avulsion fracture nonunion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The oblique view of this radiograph demonstrates a&nbsp;nonunion of a fifth metatarsal avulsion fracture (white arrow). Note the widened fracture line and sclerosis of the fractured edges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_41_26271=[""].join("\n");
var outline_f25_41_26271=null;
